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B. Abbreviations 
ActD Actinomycine D 
AIF Apoptosis-inducing factor 
ANT Adenin-nucleotide translocator 
AP-1 Activator-protein 1 
Apaf-1 Apoptotic protease activating factor 1 
APS Ammonium persulfate 
ASC Ascididemin 
ATP /dATP Adenosine-5’-triphosphate / 2’-Desoxyadenosine-5’-triphosphate 
BH Bcl-2 homology domain 
BSA Bovine serum albumine 
C. Caenorhabditis 
CAD Caspase-activated DNase 
CARD Caspase activation and recruitment domain 
CD Cluster of differentiation, nomenclature of antigenes 
CD95 Designation of cell surface antigen/cell death receptor (APO-1/Fas) 
CD95L Ligand of the CD95 receptor 
CHX Cycloheximide 
c-H2DCFDA Carboxy 2’7’-dichlorodihydrofluorescein diacetate 
DD Death domain 
DED Death effector domain 
DIABLO Direct IAP-binding protein with low pI 
DISC Death inducing signalling complex 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DR Death receptor 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
Erk Extracellular-regulated kinase 
B.  Abbreviations 2 
FACS Fluorescence-activated cell sorter 
FADD Fas-associated death domain protein 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FLICE Fas-like interleukin-1β converting enzyme 
FLIP FLICE inhibiting protein; c - cellular, v - viral 
Fmk Fluormethylketone 
FSC Forward scatter 
G Relative centrifugal force (RCF or g force) 
HBSS Hank´s bufferd saline solution 
Hepes N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HRP Horseradish peroxidase 
IAP Inhibitors of apoptosis  
JC-1 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide 
JNK c-Jun N-terminal kinase 
kDA Kilo Dalton 
m Milli 
M Molar 
MAPK Mitogen-activated protein kinases 
MMP Mitochondrial membrane permeabilisation; (OMP - outer, IMP - inner) 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
n Nano 
NAC N-Acetylcysteine 
NADH Nicotinamide adenine dinucleotid 
NF-κB Nuclear factor κB  
PAA Polyacrylamide 
PAGE Polyacrylamide gel electrophoresis 
PARP Poly(ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PCD Programmed cell death 
PHA Phythaemagglutinine 
PI Propidium iodide 
PI3K Phosphatidylinositide 3’-OH kinase 
B.  Abbreviations 3 
PMA Phorbol 12-myristate 13-acetate 
PMSF Phenylmethanesulfonyl fluoride 
PTPC Permeability transition pore complex 
PVDF Polyvinylidene fluoride 
rpm Rounds per minute 
ROS Reactive oxygen species 
RT Room temperature 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of mean 
Smac Second mitochondria-derived activator of caspases 
SSC Side scatter 
TBS-T Phosphate buffered saline solution with Tween 
TEMED Tetramethylethylenediamine 
TNF Tumour necrosis factor 
Tris Tris-hydroxymethyl-aminomethan 
VDAC Voltage-dependent anion channel 
∆ψm Mitochondrial transmembrane potential 
λ Wavelenght 
µ Micro 
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C. Introduction 
 
1 Background 
The modern pharmacotherapy has its seeds in the application of natural drugs. Extracts 
of plants or animal products are used for medicinal treatment since thousands of years. 
The knowledge of natural drugs and their potential use in medicine continuously 
increased throughout the centuries. Advanced preparative and analytical methods in 
phytochemistry led to the isolation and structural characterisation of a huge number of 
natural compounds, usually defined as secondary metabolites. The screening with 
innovative biological assays allows the verification of their active principle. These 
improvements provided the basis for rational drug discovery and have fundamentally 
contributed to the development of important pharmaceuticals of natural origin. 
 
Natural products are of great importance in the drug discovery process, particularly in 
the areas of infectious diseases and cancer. Recent analysis showed that for the period 
1989 to 1995 over 60% of the approved drugs developed in these disease areas are of 
natural origin (Cragg et al., 1997). Table 1 shows some plant- and microbal-derived 
anticancer drugs already in clinical use. 
 
drug class example source organism indication 
plant-derived    
vinca alkaloids vinblastine, vincristine Catharanthus roseus acut leukemia, lymphoma 
lignans etoposide*, teniposide* Podophyllum species acut leukemia, lymphoma 
taxanes paclitaxel, docetaxel* Taxus species breast cancer 
camptothecines topotecan *, irinotecan * Camptotheca acuminata ovarian cancer 
microbal-derived    
anthracyclines doxorubicin, daunomycin, 
idarubicin* 
Streptomyces species lymphoma, ovarian cancer 
mitosanes mitomycin Streptomyces species bladder cancer 
glycopeptides bleomycines A2 and B2 Streptomyces species testicle tumour, lymphoma
 
Table 1: Representative plant-derived and microbal-derived anticancer drugs in clinical use.               
* derived from a natural product source (e.g.semisynthetic)                
(modified adapted from Schwartsmann et al., 2002). 
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New strategies in drug discovery abandoned the exhausting, time- and capacity-
consuming screening of natural products. Synthetic compound libraries and 
combinatorial chemistry libraries were employed for high throughput screening. These 
techniques allow the easy and convenient generation and testing of large numbers of 
pure products. However, the limited structural complexity and diversity of the 
mentioned libraries constricted the identification of interesting lead structures. Natural 
products, instead, exhibit a great variety of unusual chemical structures which 
underlines an important role of secondary metabolites as important source for new 
leads. Therefore, the synergistic use of natural product chemistry and combinatorial 
chemistry constitutes a promising approach in drug discovery and development yielding 
new effective therapeutics (Grabley and Thiericke, 1999). 
 
 
Marine organisms, especially sponges, molluscs, bryozoans and ascidians represent a 
prolific source of structurally novel bioactive agents. During the past 30 years, a large 
number of new compounds with structures completely different from those isolated 
from terrestrial organisms, were successfully discovered from marine sources. The 
extreme conditions of the marine environment – light and pressure (deep sea), 
temperature and nutrients (deep-see hydrothermal vents), high salt content of the water 
– are decisive factors for the development of secondary metabolites of unprecedented 
structural diversity (Bracher F, 2002). Furthermore, due to the competition for light, 
space, and essential macro- and micronutrient within benthic communities, sessile 
marine organisms have adopted strategies that involve the use of chemical products, 
effective toxins against potential sessile competitors (Pawlik, 1993; Becerro et al., 
1997). Likewise, sessile marine organisms constitute potential substrates for fouling 
organism settlement, including bacterial colonisation. Thus, marine secondary 
metabolites additionally function as defence mechanism against fouling organisms 
(Wahl et al., 1994). Considering these facts, it is not very surprising that isolated marine 
compounds predominantly exhibit antimicrobal and cytotoxic properties. 
 
 
Cytarabine, which is used for the treatment of leukemia and lymphoma, was the first 
marine-derived anticancer agent to be developed for therapeutic application 
(Schwartsmann et al., 2001). The first marine secondary metabolite which entered 
human clinical trials was the cyclopeptide didemnin B, isolated from the ascidian 
Trididemnum solidum (Vera and Joullie, 2002). Further marine products which undergo 
clinical trials at present are listed in table 2. 
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drug class example source organism 
(type) 
development stage 
cyclopeptide Didemnin B Tridemnum solidum   phase II  
macrocyclic lactone Bryostatin 1 Bugula neritina 
(bryozoan) 
  phase II 
peptide Dolastatin 10 
(Cematodin) 
Dolabella auricularia 
(mollusk) 
  phase II 
polycyclic alkaloid Ecteinascidin 743 Ecteinascidia 
turbitana (tunicate) 
  phase II, III 
depsipeptide Kahalahide F Elysia rubefescens 
(mollusk) 
  phase I, II 
cyclodepsipeptide Aplidine Aplidium albicans 
(tunicate) 
  phase I 
 
Table 2: Current marine organism-derived anticancer drugs in development.               
(modified adapted from Schwartsmann et al., 2002). 
 
These examples show the obvious importance of isolated marine compounds as 
potential anticancer drugs. However, the insufficient supply of material for isolation, 
structure elucidation and further biological and clinical testing represents one of the 
major problem in drug development of marine compounds. Furthermore, the ecological 
consequences resulting from excessive collection of the marine organisms must be 
considered. Therefore, besides chemical synthesis, efforts are being made for the in 
vitro cultivation of marine microorganisms which are discussed to be involved in the 
biosynthesis of marine secondary metabolites (Grabley and Thiericke, 1999; Bracher F, 
2002). 
 
2 Ascididemin  
The class of pyridoacridine alkaloids and their biological activities 
Polycyclic aromatic alkaloids, possessing a planar pyrido[4,3,2-mn]acridin skeleton, 
constitute a new, emerging class of marine compounds. In 1983, Schmitz et al. isolated 
amphidemin, the first example of a pyridoacridine alkaloid, from a Pacific sponge 
(Amphimedon species) (Schmitz et al., 1983). Due to their significant biological 
activities there is currently great interest in marine pyridoacridine alkaloids. Most 
pyridoacridines exhibit in vitro cytotoxicity against a variety of tumour cell lines or 
antineoplastic activity in whole animal experiments (Molinski, 1993; Ding et al., 1999; 
Burres et al., 1989). The planar ring structure of the alkaloids promotes their 
intercalation into DNA (Burres et al., 1989). As found for several DNA intercalators, 
like doxorubicin and etoposide, pyridoacridine alkaloids target topoisomerase II, an 
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enzyme of the replication machinery (McDonald et al., 1994). The marine alkaloid 
dercitin serves as a lead compound for the development of new potential anti-HIV drugs 
(Taraporewala et al., 1992). Some pyridoacridine alkaloids were found to strongly 
stimulate the release of Ca2+ from the sarcoplasmic reticulum (Kobayashi et al., 1988b). 
A recent study reported insecticidal activity as well as specific binding to adenosine 
receptors and benzodiazepine binding sites of GABAA (γ-aminobutyrate) receptors of 
members of this structural class (Eder et al., 1998). 
 
Ascidians – the source of ascididemin 
The pentacyclic aromatic alkaloid ascididemin (figure 1) was first isolated from the 
Okinawan tunicate Didemnum species in 1988 by Kobayashi et al. (Kobayashi et al., 
1988a). Later on, Bonnard et al. (Bonnard et al., 1995) discovered ascididemin in an 
extract of the ascidian Cystodytes dellechiajei. 
 
 
N
N
N
O  
 
Figure 1: Chemical structure of ascididemin.  
 
Tunicates are marine, filter-feeding animals classified in the phylum Chordata, which 
also includes the vertebrates, subphylum Urochordata. The most familiar tunicates are 
the ascidians (sea squirts; class: Ascidiacea).            
The adult form of most tunicates shows no resemblance to vertebrate animals. The free-
swimming tunicate larva (tadpole), instead, exhibits all the characteristic chordate 
features also found in the embryos of vertebrates: a notochord, a dorsal, hollow nerve 
cord, pharyngal gill slits and a muscular post-anal tail (figure 2). During metamorphosis 
the tail and the ability to move is lost and the nervous system largely disintegrates.       
The adult sea squirts are sedentary and cylindrical or globular animals. The soft body is 
surrounded by a thick tunic which is either transparent or brightly coloured due to 
pigmentary storage. Tunicates feed by drawing water through the incurrent siphon 
(buccal) at the top of the body. Food particles are filtered from the water by the pharynx 
and are passed into the digestive system. The water leaves through the excurrent siphon 
(atrial) at the side (figure 2).                
Most solitary ascidians are hermaphrodites and reproduce by external fertilisation, 
C.  Introduction 8 
releasing eggs and sperm into the water and finally developing the larva. In addition, 
some species reproduce by budding, resulting in the formation of colonies of sea squirts. 
Within the colony the single zooids are either joined at their bases by slender stalks or 
embedded in one common tunic (figure 2). 
incurrent siphon
excurrent siphon
neural tube
intestine
(gill slits)
notochord
tunic
heartadhesive papillae
eye
incurrent siphon
excurrent siphon
tunic
intestine
(gill slits)
heart
stomach
gonad
A
B
C
 
Figure 2: Schematic illustration of the free-swimming tunicat larva (A), an adult sea squirt (B) and a 
colony of ascidians, embedded in one common matrix (C). (Cut - cuticula, Z - zooid,              
PZ - pigmentary cells, TM - tunic matrix). (The pictures were kindly provided by Dr. E. Natzer 
and Prof. Dr. G. Wanner). 
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The species Cystodytes dellechiajei is a colony forming ascidian of either deep purple or 
green color (figure 3), producing pyridoacridine alkaloids like shermilamin B, 
kuanoniamine D and ascididemin. Steffan et al. have shown that amino acids are 
precursors of shermilamine B (Steffan et al., 1993), the location of biosynthesis, 
however, yet remains unknown.  
 
A
B
 
 
Figure 3: Habit of the colonies of Cystodytes dellechiajei.                 
A, Purple species of Cystodytes dellechiajei in its natural environment (The picture was kindly 
provided by Dr. B.Steffan);                               
B, Illustration of purple and green species of Cystodytes dellechiajei (The picture was kindly 
provided by Dr. E. Natzer and Prof. Dr. G. Wanner) 
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Dr. Eva-Maria (Rottmayer) Natzer, coworker of the group of Prof. Dr. G. Wanner 
(Botanical Institute, University of Munich; SFB 369, B4), recently discovered pigment 
cells in the tunic of purple colonies of Cystodytes dellechiajei containing red 
pigmentary grains (figure 4) which are supposed to consist of pyridoacridine alkaloids 
(Rottmayer, 2001). Pigment cells are distributed throughout the whole tunic matrix with 
accumulation in the external layer of the matrix. This observation corroborates the 
hypothesis that cytotoxic secondary metabolites function as defence mechanism against 
environmental insult.  
 
 
 
 
Figure 4: Pigmenatry cells of the purple colonies of Cystodytes dellechiajei.               
A, The pigmentary grains are found within vacuoles, visualised by light microscopy/differential 
interference contrast; B, A cluster of pigmentary grains, visualised by scanning electron 
microscopy (The pictures were kindly provided by Dr. E. Natzer and Prof. Dr. G. Wanner).  
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Biological properties of ascididemin  
Reports exist of the potent Ca2+-release activity of ascididemin (Kobayashi et al., 
1988a) as well as antibacterial and antifungal properties (Lindsay et al., 1995). In 
particular, the cytotoxic potential against a variety of human solid tumour cell lines and 
human leukemia cell lines in vitro is well investigated (preclinical in vitro screening at 
the U.S. National Cancer Institute (NCI); Lindsay et al., 1995; Bonnard et al., 1995; 
Dassonneville et al., 2000; Delfourne et al., 2002). Most importantly, ascididemin was 
found to be equally toxic to drug-sensitive and multi-drug-resistant cell lines (Bonnard 
et al., 1995; Dassonneville et al., 2000). Spectroscopic measurements revealed that 
ascididemin intercalates into DNA, with preference to guanosine/cytidine (GC)-rich 
sequences (Bonnard et al., 1995). Several in vitro studies with purified enzyme proved 
the inhibitory effect on topoisomerase II (Schmitz et al., 1991; Dassonneville et al., 
2000). In contrast, whole cell experiments indicated that topoisomerase II might not be 
considered as a critical cellular target for ascididemin (Dassonneville et al., 2000). 
Recently, it was reported that ascididemin is capable of damaging DNA via the 
production of reactive oxygen species (Matsumoto et al., 2000). Additionally, 
ascididemin was recognised as a potent inducer of apoptosis in leukemia cell lines 
(Dassonneville et al., 2000).  
 
 
3 Aim of the work 
Although the cytotoxic properties of pyridoalkaloids are well known, the molecular 
mechanisms that govern the cell death are yet poorly claryfied. Therefore, the aim of the 
present work was to investigate ascididemin-mediated signalling pathways leading to 
the apoptotic cell death in human leukemia Jurkat T cells focussing on  
- the CD95 receptor system 
- the activation of caspases 
- the role of the mitochondria 
- the involvement of mitogen-activated protein kinases (MAPK).  
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4 Mechanisms of cell death 
Apoptosis and necrosis 
There are two forms of cell death eukaryotic cells can undergo, apoptosis or necrosis. 
The term apoptosis (a combination of the greek words apo – off and ptosis – falling; in 
ancient greek used as description for the “falling off” or shedding of leaves and flowers 
from trees) first appeared in the biomedical literature in 1972, coined by Kerr et al. 
(Kerr et al., 1972) to describe a structurally-distincitve form of cell death. The apoptotic 
process was recognised as a strongly regulated mechansim, expressed in the synonym of 
“programmed cell death” (PCD). Furthermore, studies on the nematode Caenorhabditis 
elegans provided evidence for the genetic basis of apoptosis which is highly conserved 
during evolution. (Note: Concerning these discoveries, S. Brenner, H.R. Horvitz and 
J.E. Sulston won the Nobel Prize in Physiology or Medicine in 2002.) 
Apoptosis, often limited to a single cell or a small group of cells, is characterised by 
chromatin condensation and internucleosomal DNA degradation. Furthermore, cell 
shrinkage is accompanied by an extensive blebbing of the plasma membrane which 
results in the separation of the cell into a number of membrane-bound vesicels 
(apoptotic bodies). Structural alterations of the cell surface (e.g. translocation of 
phosphatidylserine to the outer cell membrane) ensure that apoptotic cells are 
recognised and phagocytised by either macrophages or adjacent epithelial cells (Duvall 
et al., 1985). In vitro, the apoptotic bodies as well as the remaining cell fragments 
ultimately swell and finally lyse. This terminal phase of in vitro cell death has been 
termed “secondary necrosis”.  
Apoptosis largely occurs under physiological conditions. Necrosis, in contrast, is a 
mode of cell death that happens in response to a variety of harmful conditions and toxic 
substances, such as hyperthermia, hypoxia, ischemia and metabolic poisons as well as 
direct cellular trauma, typically affecting groups of contiguous cells. The necrotic 
process is characterised by swelling of the cytoplasm and the organelles, especially the 
mitochondria, due to an influx of water and extracellular ions. Ultimately, the plasma 
membrane ruptures and cytoplasmatic contents including lysosomal enzymes are 
released into the extracellular space. Thus, necrotic cell death is often associated with 
extensive damage of surrounding cells and an intense inflammatory response in the 
corresponding tissue. 
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Figure 5: Schematic illustration of apoptotic and necrotic cell death.                                
(adapted from Walker et al., 1988) 
 
Physiological and pathophysiological relevance of apoptosis 
Apoptosis has been recognised to be of major importance for development and tissue 
homeostasis. It is involved in the removal of surplus cells generated during mammalian 
development. During the ontogeny of many organs, for instance, an excess of cells is 
produced. At later stages of development cells are selectively removed by apoptosis to 
adjust the relative number of cells of different cell types to achieve proper organ 
function (Meier et al., 2000). 
Apoptosis in the immun system is a fundamental process in the regulation of  
lymphocyte maturation, in the assurance of self tolerance as well as in the 
downregulation of an immune response. Insufficient apoptosis leads to severe diseases 
like cancer and autoimmunity. Excessive apoptotic cell death, instead, is involved in the 
pathogenesis of AIDS, characterised by a depletion of CD4+ T helper cells (Krammer, 
2000). 
Neuronal apoptosis is necessary for the development of the nervous system. However, 
massive apoptosis is implicated in neurodegenerative disorders like Alzheimer´s 
disease, Parkinson´s disease and Huntington´s disease. The formation of toxic abnormal 
protein structures and aggregates are supposed to contribute to the apoptotic cell death 
in specific neuronal subpopulations (Yuan and Yankner, 2000).  
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5 The signal transduction of apoptosis 
Two convergent apoptotic signalling cascades have been described, referred to as  
extrinsic and intrinsic pathway. The extrinsic pathway is initiated at the cell surface by 
ligand-dependent triggering of receptors, called death receptors (DR). The intrinsic 
pathway emanates from alterations at the mitochondria level mediated by a variety of 
apoptotic stimuli including cellular stress, UV irradiation and chemotherapeutic agents. 
5.1 Receptor-mediated apoptosis 
DR are members of the tumour necrosis factor (TNF)/nerve growth factor (NGF) 
receptor superfamily and comprise a subfamily that is characterised by an intracellular 
domain, termed death domain (DD). Eight DRs have been described: TNF-R1, CD95 
(Fas, APO-1), TRAMP (TNF-R-related apoptosis-mediating protein; DR3), TRAIL-R1 
(TNF-related apoptosis-inducing ligand receptor 1; DR4), TRAIL-R2 (DR5), DR6, 
nerve growth factor (NGF-R) and ectodermal dysplasia receptor (EDA-R) (Schulze-
Osthoff, 511). Among these, TNF-R1 and CD95 are the best characterised (Ashkenazi 
and Dixit, 1998). 
 
CD95 receptor  and CD95 ligand  
The CD95 receptor (CD95) is a 45-kDa type I transmembrane protein which carries 
three cystein-rich repeats in its extracellular domain as recognition site for the 
corresponding receptor ligand (Itoh et al., 1991; Orlinick et al., 1997). CD95 is 
ubiquitously expressed on a variety of normal cells, including activated T- and B-cells 
and hepatocytes (Suda et al., 1995). High levels of CD95 expression have also been 
detected on solid tumors of the breast, ovary, colon, liver and leukemia T cells (Nagata 
and Golstein, 1995).  
The CD95 ligand (CD95L), a type II transmembrane protein of 40 kDa, is a member of 
the TNF-related cytokines (Suda et al., 1993). CD95L expression is limited and has 
been detected on activated T-cells (Suda et al., 1995), the corneal epithelium and the 
retina of the eye (Griffith et al., 1995). Some tumours also express CD95L, that has 
been considered as a defence mechanism against immunological removal (Hahne et al., 
1996). Proteolytic cleavage of the membrane-bound CD95L by metalloproteinases 
generates the less active form of  soluble CD95L (Mitsiades et al., 2001).  
 
CD95-mediated death signals 
Binding of CD95L or an agonistic antibody triggers the trimerisation of CD95, a 
process that in turn stimulates the generation of an death inducing signalling complex 
(DISC) (Dhein et al., 1992; Kischkel et al., 1995). Complex formation is initiated by the 
intracellular recruitment of the adapter protein FADD (Fas-associated death domain-
containing protein) (Chinnaiyan et al., 1996). FADD binds to the receptor via 
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homophilic interactions of the DD, present in both the intracellular part of CD95 and the 
C-terminus of FADD. FADD, in addition, contains a death effector domain (DED) at its 
N-terminus that couples to an analogous domain of procaspase-8/FLICE (Fas-like 
interleukin (IL)-1β converting enzyme) (see 1.4.2) (Muzio et al., 1996). Following its 
activation within the DISC, caspase-8 initiates the proteolytic cascade by cleavage of 
downstream substrates. 
 
APOPTOSIS
CD95
DISC
FADD
Procaspase-8
Caspase-8
Bid
apoptogenic 
factors
Caspase-3
CD95L
 
 
Figure 6: Schematic illustration of CD95-mediated apoptosis. 
 
CD95-mediated apoptotic signals may also be transmitted by the recruitment of 
molecules other than FADD and caspase-8. RIP (receptor-interacting protein), RAIDD 
(RIP-associated ICH/Ced-3-homologous protein with DD), and procaspase-2 form part 
of a further signalling cascade (Duan and Dixit, 2002). Moreover, up-regulation of 
cytoplasmic DAXX (death domain-associated protein) leads to the induction of the 
SAPK/JNK (stress-activated protein kinase/c-Jun N-terminal kinase) pathway (see 
1.4.5) (Yang et al., 1997b).  
Early signalling events of the death receptor can be blocked by cellular FLIP 
(FLICE/caspase-8 inhibitory protein) (Irmler et al., 1997). Due to its structural 
homology with caspase-8, c-FLIP interferes with the activation of caspase-8 at the 
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DISC level. The DED-containing N-terminus of FLIP binds to the FADD adaptor, thus 
blocking the association of caspase-8 with FADD and preventing caspase activation 
(Irmler et al., 1997). FLIP, first discovered in herpesviruses (v-FLIP), was supposed to 
attenuate apoptosis in order to evade the host´s immune response (Bertin et al., 1997).  
CD95-sensitive cells are classified concerning the signal transduction following 
receptor engagement. Apoptosis in typ I cells is initiated by activation of large amounts 
of caspase-8 at the DISC followed by the cleavage of caspase-3. In type II cells, instead, 
the mitochondria are involved in the signal transduction. Despite reduced DISC 
formation, caspase-8 is sufficiently activated to induce the mitochondrial apoptotic 
pathway via the cleavage of Bid (see 1.4.3) (Scaffidi et al., 1998).   
 
5.2 Caspases 
Caspases, a family of cystein-dependent aspartate-specific proteases, play a 
fundamental role in the execution of apoptosis. These enzymes were found to share 
sequence homology with the cell death protease Ced-3 of the nematode C. elegans 
(Yuan et al., 1993). To date, fourteen caspases have been identified in mammals, which 
are either involved in apoptosis or in inflammation.  
Caspases are expressed constitutively as inactive proenzyms composed of a N-terminal 
prodomain, a large (~20 kDa) and a small (~10 kDa) subunit. Activation of caspases 
occurs through proteolytic processing of the zymogen. Cleavage after aspartate-residues 
of specific tetrapeptide recognition motifs results in the separation of the prodomain, the  
large and the small subunit. Formation of an heterodimer by the formers and further 
association to a heterotetramer generates the catalytic active enzyme (Wilson et al., 
1994) (figure 7). 
Due to the high substrate specifity for aspartate-residues as cleavage sites activated 
caspases are able to process further procaspases which results in an amplifying caspase 
cascade. Gramzyme B, an aspartate-directed serin protease expressed in cytotoxic T 
lymphocytes, is the only known enzyme that also activates caspases (Thornberry et al., 
1997). 
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Figure 7: Schematic illustration showing the structures of procaspases and the activated form.                
A, The zymogen exists of a N-terminal prodomain (red), a large and a small subunit. The long 
prodomain of initiator caspases contains either a death effector domain (DED; two in the 
cases of procaspase-8) or a caspase recruitment domain (CARD; e.g. procaspase-9). 
Components of the catalytic site (blue triangle) are situated in both the large and the small 
subunit, whereby the absolutely conserved QACxG pentapeptide containing the catlaytic 
cystein is located in the former. B, Zymogens are cleaved after aspartate-residues of specific 
tetrapeptide recognition motifs (black arrows) to generate the heterodimeric active caspase.  
 
The initial processing of caspases, however, requires binding to specific adapter 
molecules, like FADD (see 1.4.1) and Apaf-1 (apoptotic protease activating factor-1; 
see 1.4.3). The interaction occurs through distinct structural motifs, including DED and 
CARD (caspase recruitment domain), present in both the caspase prodomain and its 
corresponding adapter molecule. Within the complex, the caspase precursors are in 
close proximity allowing autocatalytic activation (Salvesen and Dixit, 1999; Earnshaw 
et al., 1999). Based on the length of the prodomain, caspases involved in the apoptotic 
process can be classified as initiator caspases (caspase-2, caspase-8, caspase-9), 
characterised by long prodomains, and effector caspases (caspase-3, caspase-6, caspase-
7) with short prodomains. Effector caspases are activated by the former and are 
involved in the cleavage of death substrates.  
The morphological and biochemical changes that characterise apoptotic cell death result 
from the cleavage of death substrates. Caspases cleave essential structural components 
of the cytoskeleton such as actin which appears to be related to cell shrinkage and 
membrane blebbing (Cotter et al., 1992; Mashima et al., 1999). The externalisation of 
phosphatidylserine to the outer plasma membrane leaflet, a trigger for stimulating the 
phagocytosis of apoptotic cells by macrophages, also requires activated caspases 
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(Martin et al., 1996). Proteolysis of lamins, the major nuclear structural proteins, may 
induce apoptotic nuclear condensation (Takahashi et al., 1996). Likewise, the 
proteolytical processing of ICAD (inhibitor of caspase-activated DNase)/DFF (DNA 
fragmentation factor) results in the activation of CAD (caspase-activated DNase), an 
endonuclease responsible for the specific DNA fragmentation (Sakahira et al., 1998). 
The inactivation of PARP (poly(ADP-ribose) polymerase), an energy-consuming DNA 
repair enzym, is supposed to conserve the cellular NAD+ and ATP which, instead, could 
be utilised for the execution of apoptosis (Takahashi and Earnshaw, 1996).  
To prevent accidental or spontaneous processing of caspases, the proteolytic system is 
both regulated at the level of zymogen activation (see 1.4.1) and by direct inhibition of 
enzymatically active caspases. Several viral gene products function as caspase 
inhibitors. Of these, the best known are CrmA (cytokine responsive modifier A) from 
cowpox virus and p35 from baculovirus (Zhou and Salvesen, 2000). Both are shown to 
block CD95-mediated apoptosis by stably binding to the active site of the proteases 
(Xue and Horvitz, 1995). IAP (inhibitors of apoptosis) are endogenous regulators of 
apoptosis, first identified in baculoviruses (Crook et al., 1993; Duckett et al., 1996). A 
potent inhibition of caspase-3, -7, and –9 was observed in vitro whereby distinct IAP 
domains either directly bind to the small subunit of caspase-9 or occlude the active site 
of caspase-3 and –7 (Srinivasula et al., 2001; Huang et al., 2001).  
 
5.3 The mitochondrial apoptotic pathway 
Mitochondrial dysfunction represents a key event in the apoptotic process. It is 
characterised by mitochondrial membrane permeabilisation (MMP), which can affect 
both the inner and outer mitochondrial membrane, loss of the transmembrane potential 
(∆ψm) and the release of apoptogenic factors from the intermembrane space to the 
cytosol.  
 
The Bcl-2 family 
Members of the Bcl-2 family are intimately involved in the regulation of the MMP. The 
bcl-2 proto-oncogene was first discovered in human B-cell lymphomas and was 
identified as a homologue of the C. elegans cell survival gene ced-9 (Tsujimoto et al., 
1984; Hengartner and Horvitz, 1994).The Bcl-2 family includes pro- as well as anti-
apoptotic proteins which differ in the number of the conserved Bcl-2 homolog (BH) 
domains (figure 8). Most anti-apoptotic proteins, like Bcl-2 and Bcl-xL, show strong 
sequence conservation in all four domains, whereas pro-apoptotic proteins, including 
Bax, Bad and Bid, frequently lack the BH4 domain. The latter are subdivided in the Bax 
subfamily, members of which contain BH1, BH2 and BH3, and the “BH3-domain-only” 
proteins, that show sequence homology only within the BH3 domain (Bid, Bad) (Reed, 
1998). In viable cells anti-apoptotic proteins are localised in membranes such as the 
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outer mitochondrial membrane, the endoplasmic reticulum or the nuclear membrane, 
anchored through an additional carboxy-terminal hydrophobic domain. The pro-
apoptotic proteins, instead, are mainly found in the cytosol (Krajewski et al., 1993; 
Wolter et al., 1997). The formation of Bcl-2/Bax heterodimers and the interaction of 
Bad with Bcl-2-Bcl-xLwithin the outer mitochondrial membrane, respectively, suggests 
a neutralising competition of the proteins (Oltvai et al., 1993; Ottilie et al., 1997). 
Furthermore, Bad, Bcl-2 and Bcl-xL can be inactivated by phosphorylation (see 1.4.5) 
(Datta et al., 1997; Haldar et al., 1995; Kharbanda et al., 2000). In response to an 
apoptotic signal, Bax, for example, dimerises and translocates to the mitochondria 
where it becomes an integral pore forming membrane protein (Gross et al., 1998). 
Additionally, following CD95 treatment, Bid is cleaved at its amino terminus by 
caspase-8. Truncated Bid (tBid) also translocates to the mitochondria, inserts into the 
membrane and interacts with Bax to cause mitochondrial permeability transition 
(Desagher et al., 1999). In contrast, Bcl-2 antagonises the pore-forming activity of Bax, 
thus preventing the efflux of apoptosis-activating factors  (Martinou and Green, 2001) 
(figure 9).  
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Figure 8: Schematic illustration of the Bcl-2 family.                        
Group I comprises anti-apoptotic proteins, such as Bcl-2 and Bcl-xL , characterised by four 
short conserved Bcl-2 homology domains (BH1-BH4) and one C-terminal hydrophobic domain 
(TM) responsible for the localisation to membranes. Group II consists of pro-apoptotic 
proteins of the Bax subfamily which differ from group one in the lack of BH4. Group III 
represents the pro-apoptotic “BH-3-domain-only” proteins, either bearing the TM domain or 
not, like Bid and Bad. (adapted from Hengartner, 2000). 
 
The permeability transition pore complex 
The MMP also involves the permeability transition pore complex (PTPC), a 
multiprotein complex composed of the voltage-dependent anion channel (VDAC) of the 
outer membrane, the adenine nucleotide translocator (ANT) of the inner membrane and 
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various other proteins (Kroemer and Reed, 2000). Bcl-2 family members are supposed 
to interact with the PTPC and regulate its permeability. Several models are discussed 
for the MMP. Pore formation, for example, by opening of the ANT is accompanied by 
an decrease of ∆ψm, or vice versa. Thereupon, the inner mitochondrial membrane 
becomes permeable for water and solutes leading to matrix swelling and, ultimately, to 
the rupture of the outer membrane (Crompton, 1999). Furthermore, permeabilisation of 
the outer membrane is supposed to result from a conversion of the VDAC in a Bcl-
2/Bax-regulated fashion (Shimizu et al., 1999) (figure 9). 
 
Bcl-xL
Bad
apoptogenic factors
Bax
tBid
Bcl-2
Bcl-2
VDAC
ANT
Bcl-2Bax
 
 
Figure 9: Schematic illustration of the interaction of Bcl-2 family members and their influence on the 
mitochondrial membrane permeabilisation.   
 
Apotogenic factors 
The release of apoptogenic factors from the mitochondrial intermembrane space into the 
cytosol, primarily the translocation of cytochrome c, constitutes a critical event in the 
mitochondrial signal transduction (figure 10). Once liberated from the mitochondria, 
cytochrome c binds to Apaf-1, the mammalian homolog of C. elegans Ced-4 (see 1.4.2) 
(Zou et al., 1997). Apaf-1 contains binding sites for cytochrome c and dATP and 
oligomerises with other Apaf-1 molecules forming the apoptosome complex. The 
apoptosome recruits and binds the initiator caspase-9 (see 1.4.2). The processed 
caspase-9 is released from the multimeric complex and activates downstream effector 
caspases, thereby amplifying the caspase cascade (Saleh et al., 1999). The 
mitochondrial protein AIF (apoptosis-inducing factor) translocates to the nucleus and is 
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found to induce caspase-independent peripheral chromatin condensation and DNA 
fragmentation (Lorenzo et al., 1999). Smac/DIABLO (second mitochondria-derived 
activator of caspases; direct IAP-binding protein with low pI), an endogenous IAP 
inhibitor (see 1.4.2), sequesters IAP family members and neutralises their caspase-
inhibiting activity (Du et al., 2000).   
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Figure 10: Schematic illustration of the effects of apoptogenic factors released from mitochondria. 
 
5.4  Reactive oxygen species in apoptosis 
Reactive oxygen species (ROS) are constantly generated during aerobic metabolism. 
ROS comprise free radicals like the superoxide anion (O2. -), hydroxyl radical (.OH) and 
nitroxyl radical (NO.) as well as non-radicals including hydrogen peroxide (H2O2) and 
peroxynitrite (ONOO-). Free radicals and their derivatives are involved in important 
physiological processes such as the regulation of the vascular tone and in receptor-
mediated signalling pathways. Activated macrophages and neutrophiles produce large 
amounts of ROS involving the NADPH oxidase system as an antimicrobal defense 
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mechanism (respiratory burst) (Morel et al., 1991). The presence of non-enzymatic (e.g. 
glutathione, vitamine A, C and E) as well as enzymatic (e.g. superoxid dismutase, 
catalase and glutathione peroxidase) antioxidants ensures the tight control of ROS 
generation and the maintenance of an intracellular redox balance. Cellular dysregulation 
in favour for an increase in ROS levels, e.g. resulting from excessive stimulation of 
NADPH oxidases, the uncoupling of the mitochondrial electron transport chain or 
severe changes in the thiol/disulfide redox state, cause oxidative cellular stress. 
Oxidative stress has been implicated in the pathogenesis of cancer, neurodegenerative 
diseases, atherosclerosis, AIDS and others (Droge, 2002). 
Several studies provided evidence that ROS act as a mediator in apoptosis (Buttke and 
Sandstrom, 1994). Various chemotherapeutic drugs induce apoptosis accompanied by 
the intracellular production of ROS. Furthermore, the apoptotic response is inhibited by 
antioxidants or inducers of endogenous antioxidants (Verhaegen et al., 1995). Likewise, 
a functional role for ROS was suggested for TNF- and CD95-induced apoptosis 
(Cossarizza et al., 1995; Suzuki et al., 1998). ROS, additionally, have been shown to 
modulate the expression of CD95 and CD95L (Delneste et al., 1996; Bauer et al., 
1998). The transcription factors NF-κB (nuclear factor κB) and AP-1 (activator protein 
1), implicated in the regulation of apoptosis, are both targtes of oxidative stimuli. NF-
κB directly responds to oxidative stress in certain types of cells, whereas the activation 
of AP-1 is mainly attributed to the oxiative stress-induced MAPK signalling pathway 
(see 1.4.5) (Schreck et al., 1991; Karin, 1995).   
  
5.5 Mitogen-activated protein kinases (MAPK) and Akt 
The mitogen-activated protein kinases (MAPK) are activated in response to a variety of 
extracellular stimuli and transduce signals from the cell surface to the nucleus. 
Currently, twelve MAPK have been identified wich can be divided into three 
subfamilies. The extracellular signal-regulated kinases (Erk) are mainly activated by 
growth factors and mitogenic stimuli and have been linked to cell survival. The c-Jun 
N-terminal kinases (JNK; also referred to as stress-activated protein kinases, SAPK) 
and the p38 kinases are activated by cellular stress including heat shock, UV irradiation, 
proinflammatory cytokines, DNA damaging agents and protein synthesis inhibitors and 
are related to the induction of apoptosis (Boulton et al., 1991; Xia et al., 1995). One 
common feature of the MAPK is their activation through phosphorylation within a 
protein kinase cascade (figure 11). MAPK are phosphorylated at both threonine and 
tyrosine residues by dual specificity MAPK kinases (MAPKK). The MAPKK are 
themselves phosphorylated and activated by upstream MAPKK kinases (MAPKKK) 
(Cobb and Goldsmith, 1995). Once activated, MAPK phosphorylate their substrates at 
specific serine/threonine residues. MAPK tragets include several transcription factors, 
thus MAPK are involved in the regulation of gene expression (Davis, 1993).   
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Figure 11: Schematic illustration of the MAPK signalling cascade. 
 
Signalling pathways involving the serine/threonine kinase Akt, also termed protein 
kinase B (PKB), are implicated in cell survival. A large number of studies have 
demonstrated that activated Akt blocks apoptosis induced by diverse stimuli, including 
growth factor withdrawal, UV irradiation, DNA damage and anti-CD95 antibody 
(Kennedy et al., 1997; Mildner et al., 2002; Karpinich et al., 2002; Hausler et al., 
1998). After binding to phospholipids at the inner surface of the plasma membrane, that 
are generated by phosphatidylinositide 3´-OH kinase (PI3K), Akt is activated through 
phosphorylation both at a threonine and a serine residue (Alessi et al., 1997; Toker and 
Newton, 2000). Recent studies have proven that Akt directly targets proteins involved 
in the apoptotic signalling. Akt inactivates caspase-9 through phosphorylation, thereby 
blocking the transduction of death signals arising from mitochondrial pertubation (see 
1.4.3) (Cardone et al., 1998). Likewise, the pro-apototic Bad is inactivated by Akt-
mediated phosphorylation (Datta et al., 1997). Furthermore, Akt promotes cell survival 
by regulation of FLIP expression (see 1.4.1) (Panka et al., 2001). 
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5.6 Approaches in cancer therapy  
The apoptotic process has been recognised as an important target for therapeutic 
intervention and rational drug discovery (Nicholson, 2000; Schmitt and Lowe, 1999). 
Promising strategies in cancer therapy tend to reconstitute the ability of tumour cells to 
undergo apoptosis, in many instances lost due to genetic changes.      
For instance, the discovery that TRAIL (TNF-related apoptosis-inducing ligand) almost 
selectively induces apoptosis in tumor cells, while sparing healthy cells, revealed the 
therapeutic potential of recombinant TRAIL for cancer treatment (Ashkenazi et al., 
1999). In pre-clinical in vivo studies promising results have been obtained, however, a 
recent study showed that TRAIL exerts in vitro cytotoxicity against human hepatocytes 
(Gliniak and Le, 1999; Jo et al., 2000).  
The tumour suppressor gene p53 is a predestinated target for gene therapy since it is 
mutated in at least 50% of all human tumors. The transfer of p53-expressing 
adenoviruses has been shown to promote tumour regression in preclinical models of 
solid tumors. Greater efficacy was shown for adenovirus-mediated p53 gene therapy 
when combined with the application of DNA damaging drugs (Fujiwara et al., 1994). 
Currently, clinical phase II and III trials are underway (Ehlert and Kubbutat, 2001).  
The Bcl-2 antisense G-3139, also termed Genasense, has reached phase III of clinical 
trials for leukemia and melanoma. Co-administration studies of Bcl-2 antisense and 
conventional anticancer drugs for solid tumour as well as relapsed acute leukemia have 
proceeded into clinical phase II (Ehlert and Kubbutat, 2001).       
In 2001, the first rationally developed anticancer drug which targets a specfic 
oncoprotein was approved for chronic myelogenous leukemia (CML). Glivec® 
(STI571, Imatinib) selectively inhibits the tyrosin kinase Bcr-Abl, a fusion protein 
originated from a reciprocal translocation between chromosomes 9 and 22. The 
shortened version of chromosome 22, which is termed Philadelphia chromosome, is 
characteristic for CML and, therefore, represents an unique target for therapeutical 
intervention (Rowley, 1973; Capdeville et al., 2002).  
These few examples should demonstrate that an increased understanding of the 
molecular mechanisms that govern the apoptotic process or resistance to apoptosis in 
healthy and malignant cells provides an indispensable basis for effective and selective 
cancer therapies.   
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D. Materials and Methods 
1 Materials 
1.1 Ascididemin 
Ascididemin, isolated and synthesised according to the following protocols, was kindly 
provided by Michael Estermeier from the group of Dr. Bert Steffan (Department of 
Chemistry, University of Munich; SFB 369, A4). 
 
Isolation of ascididemin 
Green morphs of Cystodytes dellechiajei, collected in Spain, were homogenised in a 
blender and extracted first with methanol, followed by repeated extraction with 
methanol / chloroform 1:1 (v/v) containing 1% of a 30% ammonium hydroxide 
solution. The organic layers were combined, filtered, and evaporated in vacuo yielding a 
green residue. The crude extract was suspended in water and partitioned successively 
against toluene and 2-butanol. After evaporation, the toluene-soluble material was 
subjected to chromatography on a Sephadex LH-20 column (120.0 cm × 3.5 cm) using 
methanol/chloroform 1:1 (v/v) as eluent to give a fraction containing primarily 
ascididemin. Pure, brightly yellow coloured ascididemin (10.8 mg, 0.01% wet weight) 
was obtained after further purification by HPLC on a Bischoff Prontosil Eurobond C-18 
reversed-phase column (5 µm, 8 mm × 250 mm) employing a linear gradient from 
80% aqueous trifluoroacetic acid (0.1%) / 20% acetonitril up to 80% acetonitril in 30 
minutes. 
 
Synthesis of ascididemin 
Additional ascididemin (99% purity) was obtained by total synthesis according to the 
method of Bracher (Bracher F, 1989). The purity of ascididemin was evaluated by 
HPLC on an analytical Bischoff Prontosil Eurobond C-18 column (5 µm, 
4 mm × 250 mm) using the conditions described above. 
Derivatives of ascididemin were obtained by total synthesis according to Bracher 
(Bracher F, 1992) with some modifications (Lindsay et al., 1997). 
Isolated and sythesised ascididemin did not diverge in their cytotoxicity and their 
property to induce apoptosis in leukemia Jurkat T cells as determined by morphological 
apoptotic features, MTT assay and DNA fragmentation (data not shown).  
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1.2 Biochemicals, Reagents, Dyes and Solutions 
 
carboxy-H2DCFDA Molecular Probes, Eugene, OR, USA 
CD95 Ab (ZB4) Medical & Biological Laboratories Co., Nagoya, Japan 
CD95L, soluble Alexis Biochemicals, Grünberg, Germany 
CompleteTM  Roche, Mannheim, Germany 
Cycloheximide Sigma, Taufkirchen, Germany 
Etoposide Calbiochem, Bad Soden, Germany 
FCS PAA Laboratories, Cölbe, Germany 
Geniticin sulfate (G418) PAA Laboratories, Cölbe, Germany 
Hoechst 33342 Sigma, Taufkirchen, Germany 
JC-1 Molecular Probes, Eugene, OR, USA 
L-glutamine PAN Biotech, Aidenbach, Germany 
MTT Sigma, Taufkirchen, Germany 
NAC Sigma, Taufkirchen, Germany 
PHA Sigma, Taufkirchen, Germany 
PMA Sigma, Taufkirchen, Germany 
Propidium iodide  Sigma, Taufkirchen, Germany 
RPMI 1640 PAN Biotech, Aidenbach, Germany 
SB203580 (p38 inhibitor) Calbiochem, Bad Soden, Germany 
SP 600125 (JNK inhibitor) Calbiochem, Bad Soden, Germany 
Staurosporine Calbiochem, Bad Soden, Germany 
Wortmannin (PI3K inhibitor) Alexis Biochemicals, Grünberg, Germany 
zIETD-fmk (caspase-8 inhibitor) Calbiochem, Bad Soden, Germany 
zVAD-fmk (broadspectrum caspase inhibitor) Bachem, Heidelberg, Germany                           
zVDVAD-fmk (caspase-2 inhibitor) Calbiochem, Bad Soden, Germany 
 
PBS      Hanks´ balanced salt solution (HBSS) 
Na2HPO4 1.48 g    CaCl2 x 2 H2O  0.95 mM 
KH2PO4 0.43 g    KCl   5.3 mM 
NaCl 7.20 g    KH2PO4   0.44 mM 
H20 ad 1000 ml   MgCl2 x 6 H2O  0.49 mM 
    MgSO4 x 7 H2O  0.41 mM 
    NaCl   136.75 mM  
    Na2HPO4 x 2 H2O 0.34 mM 
    Hepes   20 mM  
    adjusting to pH 7.35 
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2 Cell culture    
2.1 Cell lines 
The human leukemia T cell lines Jurkat (clone J16) as well as JurkatR, which are 
deficient of CD95 (Peter et al., 1995) (kindly provided by Drs P.H. Krammer and H. 
Walczak, Heidelberg, Germany) were cultured in RPMI 1640 medium, containing 2 
mM L-glutamine (PAN Biotech, Aidenbach, Germany) and supplemented with 10% 
fetal calf serum (FCS) (PAA Laboratories, Cölbe, Germany). 
Jurkat T cells stably transfected with control plasmid (neo) or plasmid with bcl-xL or 
bcl-2 inserts (Walczak et al., 2000) (kindly provided by Drs P.H. Krammer and H. 
Walczak, Heidelberg, Germany) were cultured as described above. Every fifth passage, 
the medium was additionally supplemented with 1 mg/ml of the antibiotic geniticin 
sulphate (G418) (PAA Laboratories, Cölbe, Germany) for selection of the transfected 
cells. 
 
2.2 Culture techniques 
Cell cultivation 
Cells were cultured in culture medium in a 75 cm2 tissue culture flask (Peske, Aindling-
Pichl, Germany). Cell density was always kept under 1 x 106/ml to avoid mutations of 
the cells. Passaging of the cells was done three times a week. Experiments were 
performed with cells cultivated not longer than passage number twenty. Further 
passaging of immortalised cell lines is possible but the risk of genotypic changes 
increases. 
Cultivation and experimental incubation were performed in a cell incubator (Heracell, 
Heraeus, Hanau, Germany) at 37°C, 90% air humidity and 5% CO2. 
 
Seeding of cells 
For experiments cell concentration must be standarised by counting. Cell number was 
determined using a Fuchs-Rosenthal counting chamber (hemacytometer). The required 
cell concentration was adjusted by diluting the cell suspension with fresh culture 
medium. Cells were seeded in appropriate density in 96- or 24- well tissue culture plate 
and kept in the incubator for 12 h – 16 h before treatment. 
 
Cell freezing 
Microbal contamination or genotypic changes may appear in long-term cell cultures, 
leading to the loss of well-characterised cell lines. To prevent cell loss, cells can be 
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frozen and stored almost indefinitely at a very low temperature in liquid nitrogen          
(-196°C).  
 
Freezing medium  
RPMI 1640 70 ml 
FCS 20 ml 
DMSO 10 ml 
 
For cryoprotection dimethylsulfoxide (DMSO) is added to the freezing medium. After 
preparation the freezing medium is sterile filtered. 
 
5 x 105 cells/ml were pelleted by centrifugation (200xg, 10 min, 4°C) and resuspended 
in freezing medium. The cell suspension was equally transferred to cryovials (1.5 ml). 
Gradual decrease in temperature ensures gentle freezing: the cryovials were first put 
into a polystyrene box and placed in a –86°C freezer. After one day the vials were 
transferred to a liquid nitrogen container. 
 
Cell thawing 
The cryovial was carefully taken out of the liquid nitrogen and immediately thawed in a 
water-bath (37°C). Cells were transferred to a tissue culture flask (75 cm2) containing 
20 ml prewarmed culture medium (37°C). After 24 h medium was changed to remove 
cell debris, leaked toxic cell content and the DMSO, derived from the freezing medium. 
 
3 Measurement of cell viability 
MTT assay 
This assay is a quantitative colorimetric method for determination of cell survival and 
proliferation. The assessed parameter is the metabolic activity of viable cells. 
Metabolically active cells reduce pale yellow tetrazolium salt (MTT) to a dark blue 
water-insoluble formazan which can be, after solubilisation with DMSO, directly 
quantified. The absorbance of the formazan directly correlates with the number of 
viable cells (Mosmann, 1983). 
 
9 x 105 cells/ml (100 µl/well) were seeded in a 96-well tissue culture plate. Cells were 
either left untreated or stimulated with ascididemin in different concentrations (0.3 µM 
– 50 µM) for 24 h. Actinomycin D (1 µg/ml) was used as positive control, DMSO (1%) 
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as vehicel control. 10 µl of MTT solution (dissolved in PBS at a stock concentration of 
5 mg/ml; sterile filtered and protected from light) was added to each well and incubated 
for 2 h at 37°C in a CO2 incubator. Accumulated cristal formazan was solubilised by 
adding 190 µl DMSO to each well and gently shaking the culture plate in the dark at 
room temperautre for 1 h. Absorbance of the coloured solution was measured at λ = 550 
nm with an ELISA plate reader (SLT Spectra, SLT Labinstruments, Crailsheim). The 
absorbance in the DMSO wells was used to determine the zero inhibition growth level 
for each microtiter plate in an experiment. Statistical analysis of three independend 
experiments performed in triplicate and calculation of IC50 were performed using 
GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, California, 
USA).  
 
4 Flow cytometry 
In a flow cytometric system, large numbers of cells or particles flow within a laminar 
fluid stream in a single file passing a laser beam where they are individually evaluated. 
As the focused laser beam interacts with a cell, scattered light and, in the case of using 
fluorescent antibodies or dyes, fluorescence signals are created at the same time. The 
electronic signals are converted into digital values and are illustrated in dot plots or 
histogram plots.  
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Figure 12: Schematic illustration of a flow cytometer. 
All measurements were performed on a FACScalibur (Becton Dickinson, Heidelberg, 
Germany), equipped with an 488 nm argon-ion laser, using CellQuestTM software. 
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FACS buffer 
NaCl 8,12 g 
KH2PO4 0,26 g 
Na2HPO4 2,35 g 
KCl 0,28 g 
Na2EDTA 0,36 g 
LiCl 0,43 g 
Na-azide 0,20 g 
H2O ad 1000 ml, pH 7,37 
 
 
4.1 Determination of cell size and granularity 
The intensity of light scattered in the forward direction (FSC) generally correlates with 
cell size, the intensity of scattered light measured at 90° to the laser beam (side scatter; 
SSC) correlates with cell granularity. Changes of morphological features of apoptotic 
cells affect their light scattering properties: cell shrinkage and fragmentation reduces the 
FSC signal, increase of granularity enhances SSC. The detected signals are illustrated in 
dot plots (FSC versus SSC). Discrimination between normal and apoptotic cells can be 
made due to the distribution of the dots within the plot (Gorman et al., 1997b). 
7 x 105 cells/ml (1 ml/well) were seeded in a 24-well tissue culture plate. Cells were 
either left untreated or treated with ascididemin (5 µM) for different peroids of time. 
Cells were harvested in polypropylene tubes by centrifugation (600xg, 10 min, 4°C), 
washed with cold PBS and resuspended in a volume of 500 µl of cold PBS for flow 
cytometric analysis. Adjustments of the cytometer settings (FSC, SSC) were carried out 
with untreated control cells.  
 
4.2 Detection of apoptosis by Annexin V-FITC 
During apoptosis a number of changes in cell surface markers occur. An early event is 
the loss of asymmetry in cell membrane phospholipids, altering both the hydrophobicity 
and charge of the membrane surface. In living cells, the distribution of phospholipids is 
asymmetric, with the inner membrane containing anionic phospholipids (e.g. 
phosphatidylserine, PS) and the outer membrane having mostly neutral phospholipids. 
Upon induction of apoptosis, however, the amount of PS on the outer surface of the 
membrane increases (Fadok et al., 1992). Recognition of phospholipids by phagocytes 
in vivo results in the removal of apoptotic cells. Annexin V, a calcium-dependent 
phospholipid-binding protein, has a high affinity for PS (Vermes et al., 1995). Hence, 
FITC-labeled Annexin V can be used to identify apoptotic cells by flow cytometry. 
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Additional incubation with propidium iodide (PI) (see 2.4.3) is used to distinguish 
between viable, early apoptotic, necrotic or late apoptotic cells. Necrotic or late 
apoptotic cells will bind Annexin V-FITC and stain with PI because of membrane 
rupture while PI will be excluded from viable (FITC negative) and early apoptotic 
(FITC positive) cells. 
 
Detection of apoptosis after ascididemin treatment by Annexin V-FITC was performed 
using a Annexin V-FITC Apoptosis Detection Kit from Calbiochem (Schwalbach, 
Germany) according to the manufacturer´s instruction.      
Cells (7 x 105 cells/ml; 1 ml; 24-well tissue culture plate) were either left untreated or 
stimulated with ascididemin (5 µM) for different periods of time. Cells were harvested 
by centrifugation (1,000xg, 5 min, RT), washed with cold PBS, resuspended in a 
volume of 500 µl cold 1X Binding Buffer and incubated with 1.25 µl Annexin V-FITC 
solution for 15 min at room temperature. After centrifugation (1,000xg, 5 min, RT) the 
obtained pellet was resuspended in 500 µl 1X Binding Buffer and 10 µl PI solution was  
added. The samples were placed on ice in the dark and immediately analysed by flow 
cytometry. To set up the flow cytometer apoptosis-induced cells stained with FITC only 
(FL-1; λ em: 530 nm) and labeled with PI only (FL-2; λ em: 585 nm), respectively, were 
used. 
 
4.3 Quantification of apoptosis 
DNA fragmentation constitutes one biochemical hallmark of apoptosis. Thus, 
measurement of DNA content makes it possible to identify apoptotic cells, to recognise 
the cell cycle phase specificity and to quantitate apoptosis. For flow cytometry analysis 
of the relative nuclear DNA content the fluorescent dye propidium iodide (PI), which 
becomes highly fluorescent after binding to DNA, is most commonly used. After 
permeabilisation PI binds to DNA in cells at all stages of the cell cycle, and the intensity 
with which a cell nucleus emits fluorescent light is directly proportional to its DNA 
content. The results of the measurement are illustrated in a histogram, where the number 
of cells (counts) is plotted against the relative fluorescence intensity of PI (FL-2; λ em: 
585 nm; red fluorescence). The histogram reflects the cell cycle distribution of the cell 
population. Staining normal untreated cells with PI, most of the cells are in G0/G1 phase 
(DNA content: 2n) and emit light at a uniform frequency, depicited in the prominent 
G0/G1 peak of the histogram. Cells in G2/M phase (DNA content: 2 x 2n) emit light with 
double intensity of the G0/G1 cells and therefore appear at higher values. Cells passing 
through the S phase (DNA content between 2n and 2 x 2n) emit light of an intensity 
range that falls between the G0/G1 peak and G2/M peak. Staining procedure using a 
hypotonic buffer (see below) results in extraction of the fragmented low molecular 
weight DNA of apoptotic nuclei and leads to their decreased stainability with PI. 
Apoptotic nuclei appear as a broad hypodiploid DNA peak at lower fluorescence 
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intensity compared to nuclei in G0/G1 phase (“sub-G1”). For more exact evaluation of 
the “sub-G1” peak the logarithmic mode of PI fluorescence acquisition was used for 
experiments.  
 
PI staining solution 
Propidium iodide 50 µg 
RNAse 500 µg 
Sodium citrate 0,1% (w/v) 
Triton X-100 0,1% (v/v) 
PBS ad 1 ml  (light protection) 
 
 
7 x 105 cells/ml (1 ml/well), seeded in a 24-well tissue culture plate, were either left 
untreated or stimulated with ascididemin. The used stimulation time and concentration 
of ascididemin as well as the preincubation with inhibitors was dependent on the 
experiments performed. Cells were harvested in polypropylene tubes by centrifugation 
(600xg, 10 min, 4°C), washed with cold PBS and resuspended in 500 µl hypotonic PI 
staining solution. The tubes were placed at 4°C in the dark over night. Cell fluorescence 
(FL-2) as well as scatter characteristics (FSC/SSC) were aquired. For the adjustment of 
instrument settings untreated control cells were used. Marked regions of “sub-G1” were 
evaluated for percentage of apoptotic cells. 
 
4.4 Measurement of mitochondrial transmembrane potential (∆ψm) 
Mitochondrial dysfunction within the apoptotic process is often associated with loss of 
the mitochondrial inner transmembrane potential. One possibility to visualise alterations 
in the mitochondrial membrane potential is staining with potentiometric fluorescent 
dyes. The cationic carbocyanine dye JC-1 exhibits potential-dependent fluorescence 
emission: JC-1 accumulates in the mitochondrial matrix under the influence of ∆ψm and 
forms red fluorescent JC-1 aggregates (λ ex: 585 nm; λ em: 590 nm); mitochondrial 
depolarisation leads to a loss of JC-1 aggregates and an increase in green fluorescent 
JC-1 monomers (λ ex: 510 nm; λ em: 527 nm) (Cossarizza et al., 1996). 
 
To determine the reduction of ∆ψm, ascididemin (5 µM)-treated or untreated cells (7 x 
105 cells/ml; 1 ml; 24-well tissue culture plate) were incubated with 1.25 µg/ml JC-1 
(dissolved in DMSO at a stock concentration of 5 mg/ml; light protection), first for 10 
min in a CO2 incubator and, after transferring the samples to polypropylene tubes, for 
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further 20 min at room temperature. Alteration of membrane potential was assayed 
detecting FL-1 (green fluorescence; λ em: 530 nm).  
The fluorescence emission shift was also observed using fluorescence light microscopy 
(see 2.5.3).   
 
4.5 Measurement of ROS generation 
Apoptosis can be initiated by oxidative stress mediated by the generation of reactive 
oxygen species (ROS) (Buttke and Sandstrom, 1994). For the investigation of ROS 
levels carboxylated 2’7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) is 
commonly used (Burow and Valet, 1987). Carboxy-H2DCFDA is a cell-permeant 
indicator for reactive oxygen species, particularly peroxide, that is nonfluorescent until 
the acetate groups are removed by intracellular esterases and oxidation occurs within 
the cell yielding a green fluorescent product. The dye has two negative charges at 
physiological pH, allowing for better retention by cells.  
 
For equal loading the entire volume of all samples (7 x 105 cells/ml; 1 ml/sample) is 
pelleted by centrifugation (400xg, 10 min, 20°C). The obtained pellet is resuspended 
with 195 µl prewarmed HBSS, loaded with 5 µl of a 200 µM carboxy-H2DCFDA 
solution (dissolved in water-free DMSO at a stock concentration of 20 mM; dilution 
made with HBSS; light protection) and incubated for 30 min in a CO2 incubator. The 
dye was removed by centrifugation and washing with HBSS. The pellet was 
resuspended in adequate volume HBSS (1 ml/sample), the cell suspension was equally 
transferred to polypropylene tubes and placed into a water-bath (37°C). Carboxy-
H2DCFDA-containing cells were left untreated, stimulated with either ascididemin (5 
µM) or staurosporine (0.5 µM) as positive control and measured at different points of 
time. To estimate intracellular peroxide production, fluorescence intensity (FL-1; λ em: 
530 nm) was recorded. Cells incubated with carboxy-H2DCFDA only were employed to 
monitor basal peroxide synthesis. Fluorescence intensity was obtained as histogram 
statistics. 
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5 Microscopy 
5.1 Morphology of apoptotic cells  
Cell shrinkage, membrane blebbing and the formation of apoptotic bodies are  
characteristic events during apoptosis which can be easily detected by light microscopy.  
 
Cells (8 x 105 cells/ml; 1 ml; 24-well tissue culture plate) were either left untreated or 
stimulated with ascididemin (5 µM) for different periods of time. Cells were viewed at a 
200-fold magnification with a light microscop (Axiovert 25, Zeiss, Munich, Germany). 
 
5.2 Hoechst staining 
Cells undergoing apoptosis display an increase in chromatin condensation. 
Morphologically, the nuclei of apoptotic cells become smaller than those of normal cells 
and become hyperfluorescent when labeled with some nuclear stains. The bisbenzimide 
dye Hoechst 33342 is a cell-permeant, adenosine/thymidine (AT) selective, minor 
groove-binding DNA dye that brightly stains the condensed chromatin of apoptotic cells 
while staining the looser chromatin of viable cells only moderately.  
 
Cells (7 x 105 cells/ml; 1 ml; 24-well tissue culture plate) were either left untreated or 
treated with ascididemin (5 µM) for different periods of time. Cells were harvested by 
centrifugation (110xg; 10 min; 4°C), the obtained pellet was resuspended in 1 ml PBS. 
Each sample was stained with 10 µl Hoechst solution (dissolved in double destilled 
water at a stock concentration of 0.1 mg/ml) for 5 min at 37°C in the dark. The dye was 
removed by centrifugation (110xg; 10 min; 4°C) and washing with PBS. Condensed 
chromatin was visualised with a 200-fold magnification using a Zeiss Axiovert 25 
microscope (Zeiss, Munich, Germany), filter 02 (λ ex: 365 nm; λ em: 420 nm). 
 
5.3 JC-1  
(see 2.4.4) 
For fluorescence light microscopy sample were prepared as described under 2.4.4 with 
some modifications. Incubation with 1.25 µg/ml JC-1 was carried out for 30 min in a 
CO2 incubator. The fluorescence emission shift of JC-1 resulting from the 
mitochondrial depolarisation was visualised with a 200-fold magnification using a Zeiss 
Axiovert 25 microscope (Zeiss, Munich, Germany), filter 09 (λ ex: 450-490 nm; λ em:  
520 nm).  
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6 Fluorimetric caspase activity assay  
Most of the proteolytic cleavages during apoptosis results from the activation of 
caspases, a family of cysteine-dependent proteases. These enzymes recognise specific 
tetra- or pentapeptide motifs in their substrates and cleave exclusively on the carboxyl 
side of aspartate residues. Caspase activation can be measured by applying a synthetic 
peptide substrate which is coupled to a fluorophor. Cleavage of the fluorogenic 
substrate by the activated enzyme leads to increased fluorescence (Gurtu et al., 1997). 
The generated fluorophore is proportional to the concentration of activated caspase. 7-
amino-4-trifluoromethyl coumarin (AFC) is a commonly used fluorophore. The 
liberation of AFC shows a blue to green shift in fluorescence at an excitation 
wavelength of 390 nm and an emission wavelength of 505 nm. 
 
Activity of caspase-2 and –9 was determined using a Caspase-2 and a Caspase-9 
Activity Assay Kit (fluorometric), respectively, from Calbiochem (Schwalbach, 
Germany) according to the manufacturer’s instruction. 
Cells (1x106 cells/ml; 1 ml; 24-well tissue culture plate), either untreated or treated with 
ascididemin (5 µM) for different periods of time were collected by centrifugation 
(400xg, 10 min, 4°C), washed with cold PBS, transferred to reaction tubes and frozen at 
–20°C over night. The pellet was resuspended in 50 µl lysis buffer and incubated on ice 
for 10 min. The samples were centrifuged (500xg, 5 min, 4°C), 50 µl of the cleared 
lysat was transferred to a round-bottom 96-well microtiter plate (Greiner, 
Frickenhausen, Germany) and 50 µl of reaction buffer (containing 10 mM DTT) was 
added to each sample. 5 µl of VDVAD-AFC in case of measuring caspase-2 activity 
and 10 µl of LEHD-AFC in case of measuring caspase-9 activity were added to each 
well. Generation of free AFC at 37°C was kinetically determined by fluorescence 
measurement (λ ex: 385 nm; λ em: 505 nm) using a microplate reader (Fluostar, BMG 
GmbH, Offenburg, Germany).  
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7 Western blot analysis 
Apoptosis related proteins were investigated by Western blot analysis. 
 
7.1 Preparation of samples of whole cell lysates 
 
Lysis buffer  
Tris-HCl pH 7.5 30 mM 
NaCl 150 mM 
EDTA 2 mM 
Triton X-100 1% (v/v) 
CompleteTM (25x)   freshly added before use 
 
Lysis buffer (phosphorylated proteins) 
Hepes 50 mM 
NaCl 50 mM 
EDTA 5 mM 
Na4P2O7 x 10 H2O 10 mM 
NaF 50 mM 
Na3VO4 1 mM 
PMSF 1 mM 
Triton X-100 1% freshly added before use 
CompleteTM (25x) 
 
SDS Sample buffer (5x) 
Tris-HCl (pH 6.8) 3.125 M 100 µl 
Glycerol   500 µl 
SDS 20%   250 µl 
DTT 16%   125 µl 
Pyronin Y 5%   5 µl 
H2O ad 1000 µl   
 
 
Cells (8 x106 cells/ml; 1 ml; 24-well tissue culture plate) were either left untreated, 
stimulated with ascididemin (5 µM) or preincubated with inhibtor as indicated. Cells 
were harvested by pooling triplicates and subsequent centrifugation (400xg, 10 min, 
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4°C). The obtained pellet was washed with cold PBS and stored at –86°C over night. 
Cells were lysed in 100 µl of appropriate lysis buffer for 30 min at 4°C and 
centrifugated (10,000xg, 10 min, 4°C). After determination of protein concentration by 
the method of Bradford (Bradford M., 1976), an appropiate volume of sample buffer 
was added to the probes. After boiling at 95°C for 5 min, the samples were either stored 
at –20°C or immediately used for protein electrophoresis. 
 
7.2 Preparation of samples of cytosolic and mitochondrial fraction 
Involvement of mitochondria in apoptosis can lead to the release of various factors into 
the cytoplasm from mitochondria, e.g. cytochrome c. To detect the occurrence of certain 
proteins in the cytoplasm the separation of cytosolic and mitochondrial fraction is 
necessary. 
 
Permeabilisation buffer 
Mannitol 210 mM 
Hepes 10 mM 
EGTA 0.2 mM 
Succinate 5 mM 
Sucrose 70 mM 
BSA 0.15% freshly added before use 
Digitonin 80 µg/ml 
adjusting to pH 7.2 
 
Release of cytochrome c from mitochondria was analysed according to Leist et al. 
(Leist et al., 1998). Cells (8 x 105 cells/ml; 1 ml; 24-well tissue culture plate) were 
either left untreated, stimulated with ascididemin (5 µM) or preincubated with inhibitor 
as indicated. Cells were harvested by pooling triplicates and subsequent centrifugation 
(1500 rpm, 10 min, 4°C). Cell pellets were resuspended in permeabilisation buffer and 
incubated for 20 min at 4°C. Permeabilised cells were centrifuged (170xg, 10 min, 
4°C). The supernatant was removed and centrifuged again (13,000xg, 10 min, 4°C). The 
obtained cytosolic fraction was analysed for protein concentration, diluted with the 
appropriate volume of sample buffer and stored at –20°C for Western blot analysis. The 
remaining pellet from the first centrifugation step after permeabilisation was lysed in 
0.1% Triton / PBS (15 min, 4°C), centrifuged (13,000xg, 10 min, 4°C) and the 
supernatant containing the mitochondrial fraction was further prepared as described for 
the cytosolic fraction. 
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7.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed by denaturating SDS-polyacrylamide gel 
electrophoresis (Laemmli, 1970). This technique allows the electrophoretic separation 
of denaturated proteins according to their size. Sodium dodecyl sulfate (SDS), a highly 
negative charged detergent, solubilises proteins and leads to a constant net charge per 
mass unit. Hence, SDS-polypeptide complexes migrate toward the anode through the 
polyacrylamide gel according to their molecular weight. In addition, the differences in 
molecular shape are compensated by the loss of the tertiary and secondary structures 
because of the disruption of the hydrogen bonds and unfolding of the molecules. By 
adding of a reducing agent like dithiothreitol (DTT) disulfid bonds are cleaved and 
proteins are totally unfolded. The molecular weight of the investigated proteins is 
estimated by applying molecular weight standards (Rainbow marker RPN 720, 
Amersham, Buckinghamshire, England). Discontinuous gel electrophoresis is 
commonly used. A stacking gel that allows protein concentration in the gel, is overlaid 
on to a separation gel which allows protein separation. Percentage of acrylamide/ 
bisacrylamide gels should be chosen according to the expected molecular weight of the 
protein of interest.  
Electrophoresis was carried out in an vertical apparatus Mini Protean II (BioRad, 
Hercules, CA, USA). Two gel runs were performed in parallel. 
 
For gel preparation an acrylamide 30% / bis-acrylamide 0.8% 37.5:1 (v/v) stock 
solution (RotiphoreseTM Gel 30) from Roth (Karlsruhe, Germany) was applied. 
 
Separation gel 10%  Stacking gel 
PAA solution 30% 6.25 ml   PAA solution 30% 2.125 ml 
1.5 M Tris, pH 8.8 4.69 ml   1.25 M Tris, pH 6.8 1.25 ml 
SDS 10%  0.188 ml  SDS 10%  0.125 ml 
H2O   7.625 ml  H2O   8.75 ml 
10 min degassing     10 min degassing 
TEMED   18.75 µl   TEMED   25 µl 
APS  93.75 µl   APS   125 µl 
 
Electrophoresis buffer 
Tris base  3 g 
Glycine   14.4 g 
SDS   1.0 g 
H2O ad 1000 ml 
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Samples with equal amount of protein and the molecular weight marker were loaded 
into the slots of the prepared polyacrylamid gels. Electrophoresis was run at 100 V for 
21 min for stacking and at 200 V for 45 min for resolving of the proteins. (power 
supply: Biometra, Göttingen, Germany). 
 
7.4 Western blotting and detection of proteins 
The specific detection of proteins can be carried out after their electrophoretic transfer 
from the gel to an immobilising membrane (blotting membrane), incubation with 
specific antibodies and subsequent chemiluminescence visualisation. 
 
Anode solution I pH 10.4 Anode solution II pH 10.4 
Tris base 15 g Tris base  1.5 g 
Methanol 100 ml Methanol 100 ml 
H2O 400 ml H2O 400 ml 
 
Cathode solution pH 7.6 
ε-amino-n-caproic acid 2.6 g 
Methanol  100 ml 
H2O 400 ml 
 
TBS-T pH 8.0 
Tris base 3 g 
NaCl 11.1 g 
Tween 20 2 ml 
H2O ad 1000 ml 
 
Transfer of proteins onto a polyvinylidene fluoride (PVDF) microporous membrane 
(Immobilon-P, Millipore, Bedford, MA, USA) was performed by semi-dry blotting 
between two horizontal graphite electrodes (Fastblot B 43, Biometra, Göttingen, 
Germany). The discontinuous buffer system leads to an equal and effective protein 
transfer with sharp signals.  
The blotting membrane was cut to the size of the resolving gel and soaked for 5 min in 
methanol, H2O and anode solution II, respectively. Forming an air bubble free stack, 6 
sheets of blotting paper (BioRad, Hercules, CA, USA) impregnated with anode solution 
I, followed by 3 sheets impregnated with anode solution II, were placed on the graphite 
plate (anode). Onto this stack first the membrane, then the gel was laid and 
subsequently covered with 9 sheets of blotting paper moisturised with cathode solution.  
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Blotting was performed at a current of 0.8 mA per cm2 of blotting surface and 115 V for 
45 min. 
After transfer, the membrane was blocked with 5% (m/v) nonfat dry milk (Blotto, 
BioRad, Hercules, CA, USA) in TBS-T pH 8.0 for 1 h at room temperature to mask 
unspecific binding sites. The blocked membrane was incubated with a diluted antibody 
solution of the adequate primary antibody (see below) at 4°C overnight on a shaking 
platform. Three washing steps for 10 min in TBS-T pH 8.0 preceded the incubation for 
1 h at room temperature with the secondary horseradish peroxidase (HRPO)-labeled 
antibody. After repetition of the three washing steps, chemiluminescence detection was 
performed using Western Blot Chemiluminescence Reagent Plus (NEN Life Science 
Products, Zaventem, Belgium) and imaged by a Kodak Digital ScienceTM Image station 
440CF (NEN Life Science, Zaventem, Belgium). 
 
antibody isotype dilution company 
Bid rabbit IgG 1:2000, BSA kindly provided by X. Wang              
(Luo et al., 1998) 
Bcl-2 goat IgG 1:1000, Blotto Santa Caruz, Heidelberg, Germany 
phospho Bcl-2 (Ser70) rabbit IgG 1:1000, BSA Cell Signaling, Frankfurt/M, Germany 
Bcl-xL rabbit IgG 1:1000; Blotto Santa Cruz, Heidelberg, Germany 
Caspase-2 mouse IgG1 1,5 µg/ml, Blotto Becton Dickinson/PharMingen 
Heidelberg, Germany 
Caspase-3 mouse IgG 2a 1:1000, Blotto Becton Dickinson/Transduction Lab., 
Heidelberg, Germany 
Caspase-8 mouse IgG 2b 1:2000, Blotto Upstate Biotechnology, Lake Placid, 
USA
Caspase-9 mouse IgG1 0,5 µg/ml, Blotto Calbiochem, Bad Soden, Germany 
PARP mouse IgG1 1 µg/ml, Blotto Calbiochem, Bad Soden, Germany 
Cytochrome c mouse IgG 2b 1 µg/ml, Blotto Becton Dickinson/PharMingen 
Heidelberg, Germany 
phospho JNK    
(Thr183/Tyr185) 
mouse IgG1 1:2000, Blotto Cell Signaling, Frankfurt/M, Germany 
phospho p38     
(Thr180/Tyr182) 
rabbit IgG 1:1000, BSA Cell Signaling, Frankfurt/M, Germany 
phospho p44/42 (Erk) 
(Thr202/Tyr204) 
mouse IgG 1:2000, Blotto  Cell Signaling, Frankfurt/M, Germany 
phospho Akt (Ser473) rabbit IgG 1:1000, BSA Cell Signaling, Frankfurt/M, Germany 
 
Table 3: List of antibodies 
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7.5 Coomassie blue staining 
Nonspecific binding of dyes to protein structures allows visualisation of proteins 
separated by gel electrophoresis. This method includes fixation of proteins in ethanol-
acetic acid and a staining step. Coomasie blue staining is useful for control of equal 
protein loading and effective blotting. 
 
Staining solution Destaining solution 
Coomassie blue 0.3% Glacial acetic acid  10% (v/v) 
Glacial acetic acid 10% (v/v) Ethanol 96% 30% (v/v) 
Ethanol 96% 45% (v/v) H2O 
H2O 
filtration  
 
After Western blotting, gels were shaken with staining solution for 45 min and 
subsequently destained with destaining solution three times for 15 min. Proteins 
remained in the gel became visible as blue bands. 
 
8 Statistics 
Statistical analysis were performed using GraphPad Prism version 3.00 for Windows 
(GraphPad Software, San Diego, California , USA). Student´s t-test (unpaired, two-
tailed) and ANOVA (one-way) combined with post test Dunnett were applied as 
indicated. Analysing two groups with significantly different variances, student´s t test 
was combined with Welch´s correction.    
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E. Results 
1 Ascididemin induces apoptosis in leukemia Jurkat T cells 
1.1 Ascididemin exhibits cytotoxicity against leukemia Jurkat T cells –         
structure-activity relationship 
Ascididemin, whose chemical structure is shown in figure 13 A, showed dose-
dependent cytotoxic potency against the acute leukemia T cell line Jurkat determined by 
using the colorimetric MTT assay. Cell viability was significantly decreased upon 
stimulation with ascididemin at concentrations in the range of 0.4 µM up to 25 µM 
(figure 14). The IC50 value, i.e., the drug concentration inhibiting the mean growth 
value by 50%, was calculated as 0.6 µM.  
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Figure 13: Ascididemin (A) and its analogues 5-methoxyascididemin (B) and 5-hydroxyascididemin (C) 
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Figure 14: Dose-dependent in vitro cytotoxicity of ascididemin against leukemia Jurkat T cells.            
Cells were incubated with increasing concentrations (0.4 µM-25 µM) of ascididemin for 24 h. 
Cell viability was quantified by applying the MTT assay as described under “Materials and 
Methods”. Bars represent the mean ± SEM of three independent experiments performed in 
triplicate; *** p<0.001 represents significant differences compared to controle values, 
whereby control was set as 100% (ANOVA/Dunnett). 
 
 
 
Testing the two ring D analogues, 5-methoxyascididemin (figure 13 B) and 5-
hydroxyascididemin (figure 13 C), revealed lower cytotoxic properties for 5-
methoxyascididemin (IC50 = 6.5 µM) compared to ascididemin. 5-hydroxyascididemin 
exhibited no remarkable cytotoxic effect towards Jurkat T cells in this test system 
(figure 15). 
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Figure 15: Structure-activity relationship of the ascididemin analogues 5-methoxyascididemin and 5-
hydroxyascididemin.               
Jurkat T cells were incubated with increasing concentrations (0.4 µM-25 µM) of                     
5-methoxyascididemin (upper panel) and 5-hydroxyascididemin (lower panel) for 24 h. Cell 
viability was quantified by applying the MTT assay as described under “Materials and 
Methods”. Bars represent the mean ± SEM of three independent experiments performed in 
triplicate; * p<0.05 (ANOVA/Dunnett) represents significant differences compared to controle 
values, whereby control was set as 100%. 
 
E.  Results 45 
1.2 Ascididemin induces apoptotic cell death 
For discrimination between apoptotic and necrotic cell death, morphological criteria 
combined with commonly accepted biochemical methods were used.  
Ascididemin treated cells showed the characteristic morphological and biochemical 
features of apoptosis like membrane blebbing, cell shrinkage, chromatin condensation, 
DNA fragmentation and formation of apoptotic bodies.  
Light microscopy revealed the occurrence of cell shrinkage and apoptotic bodies after 
stimulation with ascididemin (5 µM) for 8h (figure 16). 
 
 
 
Figure 16: Ascididemin-treated Jurkat T cells exhibit characteristic morphological apoptotic features: 
Light microscopy                              
The upper pannel shows untreated control cells. Ascididemin-treated (5 µM, 8 h) cells showing 
characteristic membrane blebbing, cell shrinkage and formation of apoptotic bodies are 
depicted in the lower panel (original magnification 200-fold). 
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Changes in cell size and granularity 
A further method for detection of alteration in cell morphology was flow cytometry 
analysis of cell size and granularity. Changes in light scatter, i.e. a decrease in forward 
scatter (FSC) as a sign of lower cell size and an increase in side scatter (SSC) as a sign 
of granularity compared to control cells, are characteristic for cells dying of apoptosis. 
Two representative dot plots of untreated and ascididemin-treated Jurkat T cells (5 µM, 
24 h) are depicted in figure 17. 
 
 
 
Figure 17: Ascididemin-treated Jurkat T cells exhibit characteristic morphological apoptotic features:  
FACS analysis                   
Dot plot of untreated Jurkat T cells exhibiting almost uniform cell size and granularity (left 
panel); characteristic dot plot of apototic cells after ascididemin treatment (5 µM, 24 h; right 
panel): occurrence of a second population of apoptotic cells in the range of lower FSC and 
similar or higher SSC compared to control cells. Measurement was carried out by flow 
cytometry as described under “Materials and Methods”. 
 
 
 
Detection of phosphatidylserine translocated to the cell surface 
Ascididemin treatment led to the exposure of phosphatidylserine (PS) on the outside of 
the plasma membrane, a characteristic event in early stages of apoptosis, detected by 
Annexin V-FITC stainig and FACS analysis (figure 18). Costaining with propidium 
iodide (PI) allowed discrimination between apoptotic and necrotic cells. 
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Figure 18: Ascididemin induces translocation of phosphatidylserine to the outer cell membrane.               
FACS analysis of either untreated (left panel) or ascididemin-stimulated cells (5 µM, 8 h;  
right panel) after staining with Annexin V-FITC (FL-1) and PI (FL-2): cells appearing in the  
lower rigth quadrant show positive Annexin V-FITC staining, which indicates  
phosphatidylserine translocation to the cell surface, and no DNA stainig with PI,  
demonstrating intact cell membranes, both features of early apoptosis. Necrotic or late  
apoptotic cells would appear in the upper right quadrant: Annexin V-FITC- and PI-positive.  
The figure shows representative histograms out of three independent experiments. 
 
Hoechst staining of condensed chromatin  
Morphological changes during apoptotis also affect the nucleus. Staining apoptotic cells 
with the fluorescent dye Hoechst 33342 visualised condensed chromatin and 
fragmented nuclei in response to ascididemin treatment by fluorescence microscopy 
(figure 19). 
 
 
 
Figure 19: Ascididemin treatment of Jurkat T cells leads to chromatin condensation and fragmented   
nuclei.                                       
After treatment with ascididemin (5 µM, 8 h) cells were stained with Hoechst 33342 as  
described under “Materials and Methods”: nuclei of untreated cells show diffuse blue  
fluorescence (left panel); apoptotic nuclei exhibit bright blue fluorescence due to condensed  
chromatin (right panel). The pictures show representative photographs out of three  
independent experiments (original magnification 200-fold). 
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FACS analysis of DNA fragmentation 
Apoptotic signalling leads to activation of the nuclear endonuclease CAD which results 
in fragmentation of the genomic DNA. Analysis of propidium iodide (PI) stained nuclei 
by flow cytometry showed that ascididemin-treated cells displayed a population of 
nuclei with hypodiploid DNA content (figure 20). As depicted in the histogram of 
ascididemin-treated cells, ascididemin predominantly targeted cells in S phase. 
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Figure 20: Jurkat T cells exhibit DNA fragmentation after ascididemin treatment.                                 
FACS analysis of PI-stained nuclei of either untreated cells (A) or cells treated with 
ascididemin (5 µM) for 8 h (B) and 24 h (C) as described under “Materials and Methods”:  
the histograms show the distribution of nuclei with different DNA content; counts left of the 
“G0/G1-peak” (“sub-G1”) demonstrate the appearance of nuclei with a hypodiploid DNA 
content. 
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Statistical analysis of the “sub-G1” region revealed a significant, dose- and time-
dependent induction of apoptosis in response to ascididemin (figure 21). A 
concentration of 0.5 µM ascididemin (16 h) already showed a significant increase in the 
percentage of apoptotic cells. Treatment with 5 µM ascididemin led to a significant 
augmentation of apoptotic cells after 8 h. 
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Figure 21: Ascididemin induces apoptosis dose- and time-dependently in Jurkat leukemia T cells.       
Dose-dependent induction of apoptosis by ascididemin (upper panel): cells were incubated 
with increasing concentrations (0.5-20 µM) of ascididemin for 16 h; time-dependency of 
ascididemin-induced apoptosis (lower pannel): cells were incubated with ascididemin (5 µM) 
for the indicated time periods (0-24 h). Soluble CD95 ligand (CD95L) (100 ng/ml, 24h) was 
used as positive control. % Apoptotic cells, percentage of cells with hypodiploid DNA content 
as described under “Materials and Methods”. Bars represent the mean ± SEM of three 
independent experiments performed in duplicate; * p<0.05, ** p<0.01 significantly different 
compared to untreated control (0 h) (ANOVA/Dunnett). 
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2 The CD95 receptor/CD95 ligand system in ascididemin-induced 
apoptosis  
Several DNA damaging agents, such as doxorubicin and etoposide, have been reported 
to induce the expression of CD95 ligand (CD95L) and mediate cell death by subsequent 
interaction with the CD95 receptor (CD95) (Mo and Beck, 1999; Friesen et al., 1996).  
First, to investigate whether protein synthesis is required for ascididemin-induced 
apoptosis, Jurkat T cells were preincubated with the protein synthesis inhibitor 
cycloheximide (CHX) (Chlichlia et al., 1998). Acquisition of fragmented DNA after 
treatment with ascididemin (5 µM, 8 h) by flow cytometry showed no significant 
reduction of ascididemin-mediated DNA fragmentation in addition with CHX treatment 
(1 µg/ml, preincubation 1 h) (figure 22). In contrast, inhibition of protein synthesis by 
CHX affected DNA fragmentation after etoposide treatment (Siitonen et al., 2000). 
These data suggested that synthesis of new protein is not required for ascididemin 
mediated cell death.  
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Figure 22: Protein synthesis is not required for ascididemin induced apoptosis.                                      
Cells were either left untreated (Co) or stimulated with ascididemin (5 µM) for 8 h after 
preincubation with cycloheximide (CHX) (1 µg/ml) for 1 h. Etoposide (25 µg/ml) was used as 
positive control. % Apoptotic cells was determined by FACS analysis of DNA fragmentation as 
described under “Materials and Methods”. Bars show mean ± SEM of three independent 
experiments performed in duplicate. Ns, no significance compared to values seen in 
ascididemin-treated cells, ** p<0.01 significantly different compared to values seen in 
etoposide-treated cells (Student´s t-test). 
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Inhibition of CD95 receptor ligation 
Blocking the CD95 receptor of CD95-sensitive Jurkat T cells with a neutralising anti-
CD95 antibody (ZB4) was applied to determine whether the engagement of CD95 is 
necessary for ascididemin-induced apoptosis. Jurkat T cells preincubated with ZB4 (1 
µg/ml) for 1 h showed a significantly reduced apoptosis rate in response to soluble 
CD95L (100 ng/ml) compared to cells treated with CD95L only. In contrast, ZB4 was 
unable to diminish ascididemin (5 µM)-triggered apoptosis (figure 23). In fact, 
apoptosis was significantly increased in ZB4-pretreated and ascididemin-treated cells 
compared to cells treated with ascididemin only. This was most likely due to the 
cytotoxic potential of ZB4 itself observed in this cell system. These results indicate that 
ascididemin-induced apoptosis occurs independently of CD95L binding to the CD95 
receptor. 
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Figure 23: Ascididemin-induced apoptosis occurs independently of CD95L binding to the CD95 receptor.             
FACS analysis of DNA fragmentation of Jurkat T cells with either blocked (preincubation with 
anti-CD95 antibody ZB4, 1 µg/ml, 1 h) or unblocked CD95 receptor and subsequent addition 
of ascididemin (ASC, 5 µM) or soluble CD95L (100 ng/ml) as positive control for 24 h. Bars 
indicate mean ± SEM of three independent experiments performed in triplicate. ** p<0.01 
represents significant difference compared to values seen in ascididemin treated cells, *** 
p<0.001 represents significant difference compared to values seen in CD95L treated cells 
(Student´s t-test). 
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Induction of apoptosis despite lack of CD95 receptor  
Trimerisation, i.e. activation of the CD95 receptor does not only occur after binding of 
the CD95L but also in response to different stimuli that have been reported to directly 
induce clustering of the CD95 receptor, independently of CD95L (Aragane et al., 1998; 
Gajate et al., 2000). To examine whether ascididemin might activate the CD95 receptor 
system also by mechanisms independent of CD95L, ascididemin was applied to the 
subclone JurkatR which lacks the CD95 receptor. CD95-resistant JurkatR T cells 
underwent apoptosis in a concentration-dependent manner after stimulation with 
ascididemin for 24 h. At higher concentrations (5-20 µM) the effect was less 
pronounced than in CD95-sensitive Jurkat T cells (figure 24).  
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Figure 24: Ascididemin induces apoptosis in CD95-resistant JurkatR T cells.       
Jurkat T cells (black bars) as well as JurkatR T cells (grey bars) were either left untreated (Co) 
or incubated with ascididemin at the indicated concentrations for 16 h. Soluble CD95L was 
used as positive control. % Apoptotic cells was quantified by flow cytometry as described 
under “Materials and Methods”. Bars represent mean ± SEM of three independent 
experiments performed in duplicate. ** p<0.01 represents significant difference compared to 
values seen in Jurkat T cells, *** p<0.001 represents significant difference compared to values 
seen in Jurkat T cells (Student´s t-test). 
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3 The role of mitochondria in ascididemin-triggered apoptosis 
Besides triggering the “extrinsic “ pathway due to receptor activation, apoptotic signals 
can be mediated by a mitochondria-dependent “intrinsic” pathway. Mitochondrial 
membrane permeabilisation is a critical event in the process leading to apoptosis. 
Apoptogenic factors released from mitochondria participate in the transduction and 
amplification of apoptotic signals (Bernardi et al., 1999; Kroemer et al., 1998). 
 
3.1 Ascididemin affects mitochondrial membrane permeabilisation 
Release of cytochrome c 
To address the question whether ascididemin targets mitochondria, the release of 
cytochrome c from mitochondria into the cytosol was investigated by western blot 
analysis. Time-dependence studies revealed the appearance of cytochrome c in the 
cytosolic fraction, indicating outer mitochondrial membrane permeabilisation (figure 
25). A stepwise translocation of cytochrome c from the mitochondria into the cytosol 
was observed with significant amounts of cytochrome c detectable in the cytosol as 
early as 4 h after cell treatment with ascididemin (5 µM).  
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Figure 25: Ascididemin induces time-dependent cytochrome c release from mitochondria.     
Jurkat T cells were either left untreated (0 h) or stimulated with ascididemin (5 µM) for 
different time points as indicated. Cytosolic and mitochondrial fraction were analysed for 
cytochrome c by western blot as described under “Materials and Methods”. The figure shows 
one representative western blot out of three independent experiments. 
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Loss of mitochondrial transmembrane potential (∆ψm)   
Dissipation of the mitochondrial transmembrane potential (∆ψm) is related to increased 
inner mitochondrial membrane permeability (Kroemer and Reed, 2000). Ascididemin 
led to mitochondrial depolarisation as detected by flow cytometry as well as 
fluorescence microscopy applying the potential-sensitive dye JC-1. First signs of a loss 
of ∆ψm were already apparent 2 h after the addition of ascididemin as seen by an 
increase in FL-1 intensity (figure 26) and the occurrence of a bright green fluorescence, 
respectively (figure 27).   
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Figure 26: Ascididemin treatement leads to the dissipation of the mitochondrial membrane potential.       
FACS analysis of ascididemin-induced time-dependent ∆ψm dissipation in response to  
ascididemin (5 µM). Jurkat T cells were treated with ascididemin for the indicated time  
periods and subsequently loaded with the fluorochrome JC-1 (1.25 µg/ml) as described in  
”Materials and Methods”. An increase in green fluorescence (FL-1) is indicative of a loss of  
∆ψm. Depicted histogram shows one representative out of three independent experiments.  
 
 
 
Figure 27: Fluorescence emission shift of JC-1 due to the dissipation of the mitochondrial membrane    
 potential.               
Fluorescence microscopy photographs visualising the fluorescence emmision shift of JC-1: 
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untreated control cells exhibit bright red fluorescence (left panel), ascididemin-treated cells   
(2 h) show green fluorescence indicating mitochondrial depolarisation (right panel). Samples 
were prepared as described under “Materials and Methods”. The pictures show representative 
photographs out of three independent experiments (original magnification 200-fold).  
 
3.2 Ascididemin-induced apoptosis is a mitochondria-dependent process 
Antiapoptotic members of the Bcl-2 family, like Bcl-xL and Bcl-2, have been shown to 
block mitochondrial cytochrome c release and subsequent apoptosis in response to a 
variety of stimuli (Yang et al., 1997a; Vander Heiden et al., 1997; Scaffidi et al., 1998). 
To clarify the role of mitochondria in ascididemin-induced apoptosis, Jurkat T cells 
stably transfected with either vector alone (Jurkat/neo), vector containing bcl-xL inserts 
(Jurkat/bcl-xL), or vector containing bcl-2 inserts (Jurkat/bcl-2) were investigated for 
DNA fragmentation in response to ascididemin (figure 28). Dose-response studies 
revealed prevention of apoptosis in both cell lines overexpressing the antiapoptotic 
proteins (figure 29). These data suggest a mitochondria-dependent apoptotic signalling 
mediated by ascididemin. 
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Figure 28: Western blots demonstrating the expression level of Bcl-xL and Bcl-2 protein in Jurkat T cells  
 transfected with vectors containing either bcl-xL or bcl-2 inserts or control vector (neo). 
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Figure 29: Ascididemin induces a mitochondria-dependent apoptotic pathway.     
Overexpression of Bcl-xL or Bcl-2 inhibits ascididemin-induced apoptosis. Control cells   
(Jurkat/neo), cells overexpressing Bcl-xL (Jurkat/bcl-xL) or Bcl-2 (Jurkat/bcl-2) were incubated 
with the indicated concentrations of ascididemin for 16 h. % Apoptotic cells were quantified by 
FACS analysis of DNA fragmentation as described under “Materials and Methods”. Bars 
indicate the mean ± SD of two independent experiments performed in duplicate. 
 
4 The role of caspases in the ascididemin-induced apoptotic pathway  
The central component of apoptotic signalling is the proteolytic system of caspases, a 
family of cystein-dependent aspartate-directed proteases. These enzymes participate in a 
cascade that is triggered in response to proapoptotic signals and ends in the cleavage of 
a variety of proteins, resulting in disassembly of the cell. 
 
4.1 Ascididemin induces activation of caspase-9, -8 and –3 
To elucidate the involvement of caspases in ascididemin-mediated apoptosis the 
activation of certain caspases were determined by western blot analysis. 
Treatment of Jurkat T cells led to the activation of caspase-3, -8, and –9. Time-
dependence studies revealed the processing of procaspase-9 after 4 h of incubation with 
ascididemin (5 µM), cleavage of caspase-8 and –3, respectively occurred after 8 h 
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(figure 30). Cleavage of the caspase-3 substrate PARP showed a similiar activation 
pattern as caspase-3 (figure 31). 
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Figure 30: Caspase activation in response to ascididemin treatment.          
Representative western blots showing the time-dependent (0-24h) processing of procaspases  
(caspase-9, -8 and –3) to their active intermediates after treatment with ascididemin (5 µM)   
for different time periods. Soluble CD95L (200 ng/ml, 8 h) was used as positive control. All  
experiments were performed three times with similar results. 
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Figure 31: Ascididemin induces cleavage of PARP.              
Cells were either left untreated (0 h) or incubated with 5 µM ascididemin for different time  
periods and analysed for cleavage of PARP as described under “Materials and Methods”. The 
figure shows one representative western blot out of two independent experiments.  
 
 
 
E.  Results 58 
In regard to the kinetics of caspase activation, the processing of caspase-8, commonly 
classified as initiator caspase, occurred after cleavage of the initiator caspase-9. In 
contrast, activation of caspase-8 correlated well with the activation of the executioner 
caspase-3. Thus, these data suggest that caspase-8 rather acts as an executioner caspase 
in the apoptotic signalling mediated by ascididemin. 
 
4.2 Caspase activation is necessary for ascididemin-induced apoptosis 
To evalute the contribution of caspase activation to apoptosis induced by ascididemin 
the broadspectrum caspase inhibitor zVAD-fmk was applied. Using flow cytometry 
analysis of DNA fragmentation a complete abrogation of ascididemin-induced (5 µM) 
apoptosis after pretreatment with 25 µM zVAD-fmk for 1 h was observed (figure 32).  
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Figure 32: Inhibition of caspases by zVAD-fmk protects against ascididemin-induced apoptosis.                        
Cells were left untreated (Co), treated with ascididemin (ASC, 5 µM, 8 h), or pretreated with  
zVAD-fmk (25 µM, 1 h) and then incubated with ascididemin (ASC, 5 µM). Apoptotic cells  
were quantified by FACS as described under “Materials and Methods”. Bars represent the  
mean ± SE of three independent experiments performed in duplicate; ***p< 0.001 implicates  
significant difference compared to values seen in ascididemin-treated cells (Student´s t test). 
 
4.3 Caspase-2 
Caspase-2 is activated in response to various apoptotic stimuli, including DNA 
damaging agents, TNF-α, and CD95 ligation (Harvey et al., 1997; Duan and Dixit, 
2002; Droin et al., 2001). As caspase-2 was demonstrated to be a nuclear resident 
protein (Colussi et al., 1998; Paroni et al., 2002) and ascididemin is reported to affect 
the nucleus, the impact of caspase-2 on ascididemin-induced apoptosis was 
investigated. 
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4.3.1 Activated caspase-2 is necessary for ascididemin-induced apoptosis 
Time-response studies indicated that ascididemin (5 µM) stimulated the processing of 
procaspase-2 as early as 4h after stimulation (figure 33). Etoposide was used as positive 
control (Robertson et al., 2000).  
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Figure 33: Activation of caspase-2 in response of ascididemin treatment.            
Cells were either left untreated (0 h) or incubated with ascididemin (5 µM) for different time  
periods and processed caspase-2 was detected as described under “Materials and Methods”.  
Etoposide (25 µg/ml, 8 h) was used as positive control. The figure shows one representative  
western blot out of three independent expriments. 
 
The crucial involvement of caspase-2 in the apoptotic signalling of ascididemin was 
proven by prevention of DNA fragmentation in the presence of the specific caspase-2 
inhibitor zVDVAD-fmk (25 µM, preincubation 1 h) (figure 34).  
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Figure 34: Caspase-2 activation is required for ascididemin-induced apoptosis.          
FACS analysis as described under “Materials and Methods” of Jurkat T cells either left  
untreated (Co), treated with ascididemin (ASC, 5 µM, 8 h) or pretreated with the specific  
caspase-2 inhibitor zVDVAD-fmk (25 µM, 1 h) and subsequently stimulated with ascididemin  
(5 µM). Bars indicate the mean ± SEM of three independent experiments performed in  
duplicate; ** p< 0.01 implicates significant difference compared to values seen in  
ascididemin-treated cells (Student´s t test). 
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4.3.2 Caspase-2 acts as an initiator caspase 
The hierarchical collocation of caspase-2 within the caspase cascade is discussed 
controversially. On the one hand, caspase-2 activation is reported as an initial and very 
early event, respectively, (Harvey et al., 1997; Droin et al., 2001; Robertson et al., 
2002). On the other hand, caspase-2 has been shown to be activated downstream of  
caspase-9 and caspase-3 (Slee et al., 1999; Li et al., 1997; O'Reilly et al., 2002).  
 
Caspase-2 activation occurs upstream of mitochondria 
The fact that the processing of procaspase-2 kinetically paralleled the cleavage of 
procaspase–9 (figure 30) raises the question of whether caspase-2 acts as initiator 
caspase within the ascididemin-induced caspase cascade. To investigate at what stage in 
the apoptotic pathway caspase-2 activation occurs, Jurkat/bcl-xL cells, which are 
protected against ascididemin-induced mitochondrial apoptosis (figure 29), were 
examined for the processing of caspase-2 after treatment with ascididemin (5 µM). In 
fact, the cleavage of caspase-2 was found in both cell types in response to ascididemin 
indicating that caspase-2 activation occurs upstream of mitochondria (figure 35). 
However, in Jurkat/bcl-xL caspase-2 was activated to a lower extent than in Jurkat/neo. 
Etoposide (25 µg/ml) was used as positive control (Robertson et al., 2000).  
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Figure 35: Caspase-2 is activated upstream of mitochondria.           
Representative western blot showing the time-dependent cleavage of procaspase-2 to its active  
subunit in Jurkat/neo and Jurkat/bcl-xL cells. Control cells (Jurkat/neo) and cells  
overexpressing Bcl-xL (Jurkat/bcl-xL) were incubated with ascididemin (5 µM) for the  
indicated time periods. Etoposide (Eto, 25 µg/ml, 8 h) was used as positive control.  
Experiments were performed three times with similar results. 
 
To confirm that caspase-8 functions as an effector caspase in the apoptotic pathway of 
ascididemin, activation of caspase-8 was investigated in Jurkat/neo and Jurkat/bcl-xL. 
As depicted in figure 36, cleavage of caspase-8, in fact, only occurred in Jurkat/neo, 
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whereas overexpression of Bcl-xL prevented the activation of caspase-8. These results 
corroborate again that caspase-8 acts as an effector caspase downstream of 
mitochondria.   
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Figure 36: Processing of procaspase-8 occurs downstream of mitochondria.            
Representative western blots indicating activation of caspase-8 as a mitochondria-dependent  
event. Control cells (Jurkat/neo) and cells overexpressing Bcl-xL (Jurkat/bcl-xL) were  
incubated with ascididemin (5 µM) for the indicated time periods. Etoposide (Eto, 25 µg/ml,     
8 h) was used as positive control. Experiments were performed three times with similar  
results. 
 
Caspases contribute to the cleavage of caspase-2 
Since caspase-2 was activated to a lower extent upstream of mitochondria, an 
amplification of caspase-2 activation within the caspase cascade was supposed. Indeed, 
inhibition of active caspases by the broadspectrum caspase inhibitor zVAD-fmk (25 
µM; preincubation 1 h) led to an attenuation of processing of caspase-2 in response to 
ascididemin (5 µM, 8 h) (figure 37). 
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Figure 37: zVAD-fmk reduces activation of caspase-2.           
Jurkat T cells were either left untreated (Co) or stimulated with ascididemin (5 µM, 8 h) in the  
absence (ASC) or presence of the broadspectrum caspase inhibitor zVAD-fmk (25 µM,  
preincubation 1 h) and probed for cleavage of caspase-2 as described under “Materials and  
Methods”. The figure shows one representative western blot out of three independent  
experiments. 
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Activated caspase-2 affects cytochrome c release 
Due to the observation that caspase-2 is activated upstream of mitochondria a possible 
influence on cytochrome c release came into question. To determine whether caspase-2 
was required for ascididemin-induced cytochrome c release, Jurkat T cells were treated 
with 5 µM ascididemin for 8 h in the absence or presence of the specific caspase-2 
inhibitor zVDVAD-fmk (25 µM). The results indicated that pretreatment with 
zVDVAD-fmk for 1 h diminished translocation of cytochrome c from the mitochondria 
into the cytoplasm (figure 38). Thus, caspase-2 is considered as an important inductor of 
cytochrome c release upstream of mitochondria. 
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Figure 38: Caspase-2 inhibition affects ascididemin-triggered cytochrome c release.        
Jurkat T cells, either left untreated (Co) or treated with 5 µM ascididemin for 8 h in the  
absence (ASC) or presence of zVDVAD-fmk (pretreatment 1 h) were analysed for cytochrome c 
release by western blot analysis as described under “Materials and Methods”. The figure  
shows one representative western blot out of two independent experiments.  
 
 
Caspase-2 contributes to the cleavage of caspase-9  
Since caspase-2 inhibition attenuated ascididemin-mediated cytochrome c release the 
involvement of caspase-2 in the activation of caspase-9 was assumed. To test this 
hypothesis, Jurkat T cells were investigated for caspase-9 cleavage by western blot 
analysis. Cells were stimulated with ascididemin (5 µM) for 8 h in the absence or 
presence of the specific caspase-2 inhibitor zVDVAD-fmk (25 µM, pretreatment 1 h). 
The obtained data demonstrated that inhibition of active caspase-2 resulted in reduced 
cleavage of caspase-9 (figure 39). Hence, caspase-2 activation is supposed as an initial 
event in ascididemin-mediated apoptosis. 
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Figure 39: Processing of caspase-9 is influenced by inhibition of caspase-2.     
Representative western blot showing reduced processing of procaspase-9 into its  
intermediates in response to ascididemin (5 µM) stimulation of Jurkat T cells for 8 h with  
additional pretreatment for 1 h with the specific caspase-2 inhibitor zVDVAD-fmk (25 µM).  
The figure shows one out of three independent experiments. 
 
 
Caspase-2 is activated prior to the processing of caspase-9  
To confirm the finding of an initial activation of caspase-2, measurement of caspase-2 
activity in relation to caspase-9 activity was performed by applying fluorometric 
caspase activity assays. Following treatment of Jurkat T cells with 5 µM ascididemin 
for up to 8 h a significant increase in caspase-2 activity was already detected after 3 h of 
incubation, whereas caspase-9 is still inactive (figure 40). These data offer additional 
support that caspase-2 acts as an initiator caspase in the ascididemin-triggered apoptotic 
signalling. 
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Figure 40: Caspase-2 activity preceds caspase-9 activity.              
Comparison of caspase-2 and caspase-9 enzyme activity in Jurkat T cells treated with  
ascididemin (5 µM) for the indicated time periods. Measurement was performed by the  
fluorometric VDVAD-AFC cleavage assay and LEHD-AFC cleavage assay, respectively, as  
described under “Materials and Methods”. Bars represent the mean ± SD of three  
independent experiments performed in duplicate. * p<0.05, ** p<0.01 significantly different  
compared to untreated control (0 h) (ANOVA/Dunnett). 
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Activated caspase-2 cleaves Bid  
The proapoptotic protein Bid transduces the apoptotic signal from activated caspase-8 to 
mitochondria in the CD95 receptor mediated signalling cascade. In vitro studies 
demonstrated that also recombinant active caspase-2 is able to cleave Bid (Paroni et al., 
2001). To investigate whether caspase-2 transduces the apoptotic signal via cleavage of 
Bid in this system, Jurkat T cells were stimulated with ascididemin (5 µM, 8 h) in the 
presence or absence of the specific caspase-2 inhibitor zVDVAD-fmk (25 µM, 
pretreatment 1 h). The results revealed Bid as a target of activated caspase-2 in the 
response of ascididemin treatment (figure 41).  
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Figure 41: Activated caspase-2 cleaves Bid.            
Representative western blot showing abrogation of Bid cleavage in response to pretreatment  
with 25 µM of the specific caspase-2 inhibitor zVDVAD-fmk (1 h) and subsequent stimulation  
with ascididemin (5 µM, 8 h) in comparison of treatment with ascididemin alone. Soluble   
CD95L (100 ng/ml, 8 h) alone as well as preincubation with zIETD-fmk, the specific caspase-8 
inhibitor, (10 µM, 1 h) followed by stimulation with soluble CD95L were used as positive  
control. The figure shows one out of three independent experiments. 
 
 
5 Ascididemin treatment leads to generation of reactive oxygen 
species  
Oxidative stress has been proposed as a potential mediator of apoptosis (Buttke and 
Sandstrom, 1994). Anticancer drugs like camptothecin and actinomycin D have been 
shown to rapidly produce reactive oxygen species (ROS) during the induction of 
leukemic cell apoptosis (Creagh and Cotter, 1999; McGowan et al., 1996; Gorman et 
al., 1997a). Matsumoto and coworkers showed that ascididemin is able to cleave 
isolated plasmid DNA mediated by ROS in vitro (Matsumoto et al., 2000). To assess 
initial intracellular peroxide production in Jurkat T cells FACS analysis was performed 
empolying the redox-sensitive fluorescent dye carboxy-H2DCFDA. Ascididemin 
treatment (5 µM) of Jurkat T cells caused a significant peroxide production as early as 
30 min after stimulation (figure 42). Staurosporine (0.5 µM) was used as positive 
control (Cai and Jones, 1998).  
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Figure 42: Ascididemin induces generation of reactive oxygen species in Jurkat T cells.          
Cells were preloaded with 5 µM carboxy-H2DCFDA and exposed to 5 µM ascididemin. At  
indicated time points, the intracellular fluorescence was quantified by flow cytometry as  
described in “Materials and Methods”. Bars indicate the mean ± SE of three independent  
experiments performed in duplicate. * p<0.05, ** p<0.01 significantly different compared to  
values seen in untreated control cells (0 min) (ANOVA/Dunnett).  
 
 
 
To elucidate if ROS play a critical role in the apoptotic process mediated by 
ascididemin, DNA fragmentation of ascididemin treated Jurkat T cells (5 µM; 8 h) was 
assessed in the presence or absence of 20 mM N-acetylcysteine (NAC), a well 
established thiol antioxidant. Pretreatment of NAC did not alter the rate of apoptotic 
cells in comparison to the rate obtained for ascididemin alone (figure 43). These data 
suggest that ROS do not affect late apoptotic events in ascididemin-induced apoptosis.  
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Figure 43: N-acetylcysteine (NAC) does not reduce ascididemin-triggered DNA fragmentation.         
Cells were left untreated (Co), treated with ascididemin (ASC, 5 µM, 8 h), or pretreated with  
NAC (20 mM, 1 h) and then incubated with ascididemin (ASC, 5 µM). Apoptotic cells were  
quantified by FACS as described under “Materials and Methods”. Bars represent the mean ±  
SEM of three independent experiments performed in duplicate; ns p> 0.05 implicates no  
significance compared to values seen in ascididemin-treated cells (Student´s t test). 
  
 
6 The role of MAPK and Akt in ascididemin-triggered apoptosis 
6.1 The activation of MAPK  
In response to oxidative stress the activation of mitogen-activated protein kinases 
(MAPK) have been reported (Shiah et al., 1999; Banno Y. et al., 2001). The activation 
of c-Jun N-terminal kinases (JNK) and p38 kinases is mainly correlated with cell death 
or apoptosis. In contrast, activated extracellular signal-regulated kinases (Erk) are 
related to cell survival and proliferation. Given the generation of ROS by ascididemin, 
activation of JNK, p38 and Erk, three subfamilies of the MAPK, could be considered. 
To address this question, western blot analysis of phosphorylated, i.e. activated, MAPK 
was performed. Time-course studies clearly detected phosphorylated p38 and JNK after 
treatment with ascididemin (5 µM) for 2 h and 4 h, respectively (figure 44 ). 
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Figure 44: Phosphorylation of p38 and JNK following ascididemin treatment in Jurkat T cells.         
Cells were either left untreated or treated with ascididemin (5 µM) for the indicated time  
periods and probed for phosphorylation of p38 (upper panel) and JNK (lower panel),  
respectively, by western blot analysis as described under “Materials and Methods”. The  
figure shows one representative western blot out of three independent experiments for each  
kinase. 
 
 
In contrast, the level of phosphorylated Erk was unaltered, rather slightly decreased, in 
response to ascididemin treatment (figure 45). Phytohaemagglutinine (PHA) in 
combination with phorbol 12-myristate 13-acetate (PMA), a known activator of the Erk 
cascade, was used as positive control (Li et al., 1999).   
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Figure 45: Erk is not phosphorylated in response to ascididemin treatment of Jurkat T cells.         
Cells were either left untreated or treated with ascididemin (5 µM) for the indicated time  
periods and probed for phosphorylation of Erk by western blot analysis as described under 
“Materials and Methods”. PHA (1 µg/ml)/PMA (100 nM) treatment (5 min) was used as  
positive control. The figure shows one representative western blot out of three independent  
experiments. 
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6.2  Influence of activated JNK and p38 on ascididemin-mediated apoptosis 
The impact of activated MAPK in apoptosis is highly divergent. Apoptotic as well as 
anti-apoptotic influences during the response to different stimuli are reported (Ortiz et 
al., 2001; Xia et al., 1995; MacFarlane et al., 2000; Lenczowski et al., 1997). The 
precise role of these activated kinases appears to be largely dependent on cell typ and 
stimulus. To examine the influence of activated p38 and JNK on ascididemin-induced 
apoptosis in Jurkat T cells, DNA fragmentation was measured by FACS analysis 
employing the specific kinase inhibitors SB203580 (Young et al., 1997) and SP600125 
(Bennett et al., 2001), respectively. Both inhibit the catalytic activity of the specific 
kinase. Preincubation with the p38 inhibitor SB203580 (10 µM; 45 min) did not alter 
the rate of ascididemin-mediated apoptosis (5 µM; 8 h), indicating that activation of p38 
occurs without any relevance to the apoptotic signalling (figure 46, left panel). In 
contrast, application of the JNK inhibitor SP600126 (10 µM; 15 min) caused a 
significant reduction of DNA fragmentation (figure 46, right panel). Due to the fact that 
DNA fragmentation could be blocked only partially by SP600125, the role for active 
JNK to the apoptotic pathway of ascididemin is rather contributory. 
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Figure 46: Causal involvement of active p38 and active JNK in ascididemin-mediated apoptosis.       
FACS analysis of DNA fragmentation in Jurkat T cells was performed as described in 
“Materials and Methods”. Cells were either preincubated with the specific inhibitor of p38  
(SB203580, 10 µM, 45 min) (left panel) and the specific inhibitor of JNK (SP600125, 10 µM,  
15 min) (right panel), respectively, and subsequently stimulated with ascididemin (ASC, 5 µM,  
8 h) or treated with ascididemin alone, as indicated. Control cells (Co) were left untreated.  
Bars represent the mean ± SEM of three independent experiments performed in duplicate. Ns   
p>0.05 no significance compared to values seen in ascididemin-treated cells, * p< 0.05   
significantly different compared to values seen in ascididemin-treated cells (Student´s t-test). 
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JNK activation occurs upstream of mitochondria 
Some reports demonstrated that Bcl-xL and Bcl-2 are able to inhibit the induction of 
JNK (Srivastava et al., 1999; Park et al., 1997). Therefore, a possible relationship 
between mitochondrial pertubation and phosphorylation of JNK was examined. 
Overexpression of Bcl-2 or Bcl-xL in Jurkat T cells abolished apoptosis in response to 
ascididemin (figure 29). However, no difference in ascididemin-induced activation of 
JNK was detected in these cell lines compared to control cells (Jurkat/neo) (figure 47). 
These results indicate that JNK is activated independently of mitochondrial events. 
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Figure 47: JNK activation occurs upstream of mitochondria.        
Control cells (Jurkat/neo) and cells overexpressing Bcl-xL (Jurkat/bcl-xL) and Bcl-2 
(Jurkat/bcl-2) were incubated with ascididemin (5 µM) for the indicated time periods. Western 
blot analysis of phosphorylated JNK was carried out as described under “Materials and 
Methods”. The figure shows one representative out of three independent experiments.  
 
 
Activation of JNK is necessary for cytochrome c release 
Previous studies reported that JNK is able to translocate to and directly activate 
mitochondria (Kharbanda et al., 2000; Aoki et al., 2002), and that JNK is required for 
cytochrome c release (Tournier et al., 2000). Employing the specific JNK inhibitor 
SP600125 (10 µM; preincubation 45 min) a putative impact of activated JNK on the 
mitochondrial release of cytochrome c into the cytoplasm in response to ascididemin 
treatment (5 µM; 6 h) was investigated. Western blot analysis confirmed a strong 
impact of active JNK on cytochrome c release in Jurkat T cells (figure 48). 
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Figure 48: Activated JNK is required for cytochrome c release.         
Jurkat T cells were either left untreated (Co), treated with ascididemin (ASC, 5 µM, 6 h) alone 
or pretreated with the JNK inhibitor SP600125 (10 µM, 45 min) and then incubated with 
ascididemin (5 µM). Sample preparation and western blot analysis was performed as 
described under “Materials and Methods”. Experiments were performed three times with 
similar results.  
 
 
Bcl-2 as possible target of JNK 
Several studies demonstrated that phosphorylation and therefore inactivation of the anti-
apoptotic protein Bcl-2 is associated with cell death (Haldar et al., 1995). JNK was 
found to mediate the phosphorylation of Bcl-2 (Maundrell et al., 1997; Yamamoto et 
al., 1999). To test whether Bcl-2 is phosphorylated in response to ascididemin 
treatment, western blot analysis was performed. In contrast to taxol (1 µM), used as 
positive control (Yamamoto et al., 1999), ascididemin did not induce phosphorylation 
of Bcl-2 (figure 49).      
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Figure 49: Ascididemin does not induce phosphorylation of Bcl-2.        
Jurkat T cells were treated with ascididemin (5 µM) for the indicated time periods and probed 
for phosphorylated Bcl-2 as described under “Materials and Methods”. Taxol (1 µM, 24 h) 
was used as positive control. Experiments were performed three times with similar results. 
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6.3 The activation of Akt 
Akt is activated by ascididemin 
The PI3K-regulated protein kinase Akt plays, like Erk, a critical role in cell survival. 
Western blot analysis exhibited that ascididemin (5 µM) activated Akt in Jurkat T cells 
in a time-dependent manner up to 8 h (figure 50).  
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Figure 50: Ascididemin activates Akt in Jurkat T cells.            
Cells were either left untreated or treated with ascididemin (5 µM) for the indicated time 
periods and analysed for phosphorylation of Akt by western blot analysis as described under 
“Materials and Methods”. Figure shows one representative western blot out of three 
independent experiments. 
 
 
Activated Akt does not affect ascididemin-induced apoptosis 
Tang et al. (Tang et al., 2001) could show that activated Akt delays etoposide-induced 
apoptosis. To investigate a potential significance of the active survival kinase Akt in the 
apoptotic pathway of ascididemin, Jurkat T cells were treated with ascididemin (5 µM) 
in the presence or absence of wortmannin (50 nM; 45 min preincubation), a PI3K 
inhibitor, and monitored for DNA fragmentation by flow cytometry. Indeed, inhibition 
of PI3-kinase by wortmannin abolished the ascididemin-induced phosphorylation of its 
downstream mediator Akt (figure 51, left panel). However, inhibition of Akt activation 
did not change the rate of apoptosis compared to ascididemin treatment alone (figure 
51, right panel). Together, these data show that activation of the survival kinase Akt is 
without any relevance to the apoptotic process triggered by ascididemin.  
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Figure 51: Activated Akt does not affect ascididemin-induced apoptosis.                          
One representative western blot out of three showing the inhibitory effect of wortmannin (50 
nM, preincubation 45 min) on Akt phosphorylation in response to ascididemin treatment (5 
µM, 2 h) (left panel). Jurkat T cells were either treated with ascididemin (5 µM, 8 h) alone or 
pretreated with the PI3K inhibitor wortmannin (50 nM, preincubation 45 min) and 
subsequently stimulated with ascididemin. Control cells (Co) were left untreated (right panel). 
FACS analysis of DNA fragmentation was performed as described under “Materials and 
Methods”. Bars indicate the mean ± SEM of three independent experiments performed in 
duplicate. Ns implicates no significance compared to values seen in ascididemin-treated cells  
(Student´s t-test). 
 
 
7 The signalling upstream of mitochondria 
Since it was shown that caspase-2 (see 3.4.3.2) as well as JNK (see 3.6.1.3) act 
upstream of mitochondria, it should be clarified whether a cross-talk exists between the 
caspase signalling and the MAPK pathway.   
7.1 Role of ROS in the activation of JNK and caspases 
Cellular oxidative stress is a key mediator for activating members of the MAPK 
pathways, e.g. the JNK pathway. In order to determine if phosphorylation of JNK is 
induced by ROS, Jurkat T cells were treated with ascididemin (5 µM, 4 h / 8 h) in the 
presence or absence of N-acetylcysteine (NAC). JNK phosphorylation was almost 
completely blocked by NAC only at the early time point (4 h), indicating that ROS is 
essential for the initial activation of the JNK pathway (figure 52).  
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Figure 52: N-acetylcysteine (NAC) blocks phosphorylation of JNK at early time points.       
Jurakt T cells were either left untreated (Co), treated with ascididemin (5 µM) for 4 h (left 
panel) and 8 h (right panel), respectively, or pretreated for 1 h with NAC (20 mM) and 
subsequently stimulated with ascididemin (5 µM). Phosphorylated JNK was detected by 
western blot analysis as described under “Materials and Methods”. The figure shows one 
representative western blot out of three independent experiments. 
 
 
To test a possible impact of ROS on the processing of caspases, cells were treated as in 
the experiment described above. Western blot analysis detecting caspase-2 and caspase-
9 revealed a selective abrogation of caspase cleavage in response to NAC pretreatment 
followed by ascididemin incubation. Processing of caspase-2 was unaffected by NAC, 
whereas cleavage of caspase-9 was abolished (figure 53). These data indicate that 
activation of caspase-2 occurs independently of ROS. However, ROS are involved in 
the activation of caspase-9.   
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Figure 53: NAC selectively inhibits caspase cleavage.          
Jurakt T cells were either left untreated (Co), treated with ascididemin (5 µM, 4 h) or 
pretreated for 1 h with NAC (20 mM) and subsequently stimulated with ascididemin (5 µM). 
Cleavage of caspase-2 (left panel) and caspase-9 (right panel), respectively, was detected by 
western blot analysis as described under “Materials and Methods”. The figure shows one 
representative western blot out of three independent experiments. 
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7.2 Activated JNK contributes to caspase activation 
To identify putative interactions between the signalling pathway of caspases and the 
regulation of phosphorylation of JNK, the broadspectrum caspase inhibitor zVAD-fmk 
was used. Pretreatment for 1 h with zVAD-fmk (25 µM) and subsequent incubation 
with ascididemin (5 µM, 8 h) did not interfere with JNK phosphorylation, 
demonstrating that the activation of JNK occurs independently of active caspases 
(figure 54). 
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Figure 54: Caspase inhibition by zVAD-fmk does not interfere with JNK phosphorylation.      
Jurkat T cells were either left untreated (Co), treated with ascididemin (5 µM, 8 h) or 
pretreated for 1 h with the broadspectrum caspase inhibitor zVAD-fmk (25 µM) and 
subsequently stimulated with ascididemin (5 µM). JNK phosphorylation was detected by 
western blot analysis as described under “Materials and Methods”. The figure shows one 
representative western blot out of three independent experiments. 
 
 
 
On the other hand, inhibition of caspase-2 and caspase-9 activation by the specific JNK 
inhibitor SP600125 suggested a contributory role of active JNK to the activation of 
caspase-2 and caspase-9 at least at early time points (4h) (figure 55). 
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Figure 55: Cleavage of caspase-2 and caspase-9 is reduced by the specific JNK inhibitor SP600125 at 
early time points.             
Jurkat T cells were either left untreated (Co), treated with ascididemin (ASC, 5 µM, 6 h) alone 
or pretreated with the specific JNK inhibitor SP600125 (10 µM, 45 min) and then incubated 
with ascididemin (5 µM). Sample preparation and western blot analysis was performed as 
described under “Materials and Methods”. Experiments were performed three times with 
similar results.  
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F. Discussion 
 
The marine pyridoacridine alkaloid ascididemin has previously been shown to exhibit 
antitumour properties against different cancer cell lines (Delfourne et al., 2002; 
Bonnard et al., 1995). Aim of the present studies was to clarify its cytotoxic effect 
towards the human acute leukemia T cell line Jurkat with emphasis on the apoptotic 
signalling pathway triggered by ascididemin.  
 
 
1 Ascididemin-induced apoptosis in Jurkat T cells  
1.1 Cytotoxicity of ascididemin and two analogues  
The results obtained by applying the MTT assay demonstrate that ascididemin exhibits 
marked dose-dependent cytotoxic potency against Jurkat T cells in vitro with an IC50 
value of 0.6 µM.  
Concerning the structure-activity relationship of ascididemin, Lindsay et al. showed that 
the nitrogen in ring A and a completed ring E are prerequisites for the biological activity 
of ascididemin (Lindsay et al., 1995). Furthermore, a previous study reported that the 
ring D-analogue 5-methoxyascididemin showed improved cytotoxic activity against 
solid tumours. The effects, however, were strongly dependent on the cancer cell line 
(Delfourne et al., 2002). Compared to the parent alkaloid, 5-methoxyascididemin 
showed a lower level of cytotoxicity towards Jurkat T cells, demonstrated by a 10-fold 
higher IC50 value (IC50 = 6.5 µM). Moreover, 5-hydroxyascididemin failed to show any 
relevant cytotoxic properties. In conclusion, the substitution pattern of 5-
methoxyascididemin and 5-hydroxyascididemin negatively affects the cytotoxic activity 
of the natural compound ascididemin against the human leukemia cell line Jurkat.  
 
1.2 Ascididemin induces apoptotic cell death in Jurkat T cells 
The induction of apoptosis in response to the exposure of cytotoxic drugs is subject of 
intense investigation. Apoptosis is charactarised by a variety of distinct morphological 
and biochemical features that are used to discriminate the apoptotic cell death against 
necrosis. Commonly accepted methods were used to evaluate ascididemin-induced cell 
death in Jurkat T cells.   
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Light microscopy combined with flow cytometry visualised the occurrence of the 
characteristic cell shrinkage and formation of apoptotic bodies in response to 
ascididemin treatment. Alterations of the cell membrane, namely translocation of 
phosphatidylserine to the outer cell membrane, was detectable by flow cytometry using 
Annexin V-FITC. Costaining with propidium iodide (PI) allowed to clearly exclude 
necrotic cell death.  
Apoptotic morphological changes concerning the nucleus were detected by staining of 
condensed chromatin with Hoechst 33342 and subsequent fluorescence microscopy. 
Flow cytometry of PI stained nuclei revealed DNA fragmentation in a dose- and time-
dependent manner. Ascididemin, a DNA damaging agent due to its intercalating 
properties, predominantely targets cells in the S phase. 
 
 
2 Ascididemin-induced apoptosis occurs independently of a functional 
CD95 receptor/CD95 L interaction in Jurkat T cells 
 
The CD95 receptor is expressed on most T-acute lymphatic leukemia (T-ALL) cell lines 
such as Jurkat and on leukemic cells from patients. However, the contribution of the 
CD95 pathway to the cytotoxic activity of anticancer drugs remains controversial. 
Anticancer drugs, like the DNA damaging topoisomerase II enzyme inhibitors etoposide 
and doxorubicin, have been shown, with some exceptions (McGahon et al., 1998), to 
enhance both CD95 receptor and CD95 ligand (CD95L) expression on tumor cells 
(Micheau et al., 1997; Mo and Beck, 1999; Siitonen et al., 2000). However, the concept 
of involvement of the CD95 receptor/CD95L system in drug-induced apoptosis (Fulda 
et al., 2000; Friesen et al., 1996) has been challenged by several recent studies 
(Villunger et al., 1997; Micheau et al., 1999; Siitonen et al., 2000; Eischen et al., 1997): 
though CD95L is upregulated, the apoptotic cell death occurs independently of CD95 
signalling. Direct activation of the CD95 receptor independent of death receptor ligand 
ligation has also been proposed (Gajate et al., 2000; Aragane et al., 1998).  
The present data show that functional CD95 receptor/CD95L interaction is not a 
prerequisite for ascididemin-triggered apoptosis in Jurkat T cells. Inhibition of protein 
synthesis with cycloheximide (CHX) provided evidence that ascididemin-triggered 
apoptosis did not require synthesis of new protein. Thus, the requirement of new 
CD95L expression can be ruled out. Inhibition of CD95 receptor engagement with a 
neutralising anti-CD95 antibody (ZB4) had no effect on the rate of apoptotic cells 
compared to unblocked cells. This observation supports the assumption of an apoptotic 
signalling independent of a functional CD95 receptor/CD95L interaction. JurkatR T 
cells, a CD95-resistant Jurkat subline characterised by the lack of expression of receptor 
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protein, were also sensitive for ascididemin-induced apoptosis in a dose-dependent 
manner.  
However, at higher concentrations of ascididemin, the rate of apoptotic cells was 
slightly decreased in comparison to CD95-sensitive Jurkat T cells. This observation 
might point to the requirement of intracellular events at the receptor level for the 
apoptotic signalling mediated by high concentrations of ascididemin. Micheau et al. 
were able to show that anticancer drugs can induce trimerisation of the CD95 receptor 
independently of CD95L as well as the recruitment of the adapter molecule FADD to 
the receptor in the cytotoxic process leading to apoptosis (Micheau et al., 1999). 
However, the recruitment of the CD95 receptor might rather contribute to than playing a 
major role in the apoptotic signal transduction of ascididemin.  
 
 
3 Mitochondria play a critical role in ascididemin-triggered apoptosis 
 
Besides the death receptors, mitochondria play a central role in the transduction of 
apoptotic signals triggered by many stimuli. Mitochondrial membrane permeabilisation 
and the release of apoptogenic factors, e.g. cytochrome c, are key events in the process 
leading to apoptosis (Kroemer and Reed, 2000). Anti-apoptotic proteins of the Bcl-2 
family, like Bcl-xL and Bcl-2, exert their protective effect at the mitochondrial level 
(Yang et al., 1997a; Decaudin et al., 1997).   
The results of the present work show that, indeed, redistribution of cytochrome c into 
the cytoplasm occurred in response to ascididemin treatment. Translocation of 
cytochrome c from the mitochondrial intermembrane space to the cytosol occurs in 
consequence of outer mitochondrial membrane permeabilisation (OMP). Inner 
mitochondrial membrane permeabilisation (IMP) is manifested as a dissipation of the 
transmembrane potential (∆ψm). In most cases mitochondrial dysfunction implicates 
both, OMP and IMP. However, OMP and IMP are not necessarily coupled as shown for 
staurosporine (Bossy-Wetzel et al., 1998). Determination of a reduction in ∆ψm by 
using the fluorochrome JC-1 indirectly evidenced IMP in Jurkat T cells treated with 
ascididemin. The decrease of ∆ψm  preceded the release of cytochrome c. Together these 
data clearly indicate that ascididemin induces mitochondrial dysfunction in Jurkat T 
cells.  
The present data further demonstrate a causal involvement of mitochondria in 
ascididemin-mediated apoptosis, as overexpression of the anti-apoptotic proteins Bcl-xL 
or Bcl-2 protected cells from cell death.  
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4 Activated caspases are essential for the ascididemin-induced 
pathway  
 
Caspases, intracellular cystein proteases, play an essential role in the initiation and 
execution phases of both receptor- and chemical-induced apoptotic cell death. However, 
the number of studies, however, proposing an additional caspase-independent cell death 
is growing (Mathiasen et al., 1999; Roberts et al., 1999; Nylandsted et al., 2000). 
As it is demonstrated in the present work, ascididemin triggers the activation of the 
initiator caspase-8, and –9, respectively, and the executioner caspase-3. Cleavage of its 
substrate poly(ADP-ribose) polymerase (PARP) confirmes active caspase-3. The fact 
that DNA fragmentation was entirely abrogated by the broadspectrum caspase inhibitor 
zVAD-fmk provides evidence for the essential role of activated caspases in the signal 
transduction. Interestingly, the early processing of procaspase-9, the apical caspase in 
the mitochondrial pathway, was followed by the simultaneous cleavage of procaspase-8 
and procaspase-3. In regard to the kinetics, caspase-8 can be considered to act as an 
executioner caspase in the apoptotic signalling triggered by ascididemin, concomitant 
the findings of a CD95 receptor-independent apoptotic signalling (see 3.2) (Engels et 
al., 2000; Dirsch et al., 2002). The failure of cleavage of caspase-8 in Bcl-xL 
overexpressing Jurkat T cells underlines the classification as a downstream caspase. 
 
 
5 Caspase-2 acts as initiator caspase in ascididemin-mediated 
apoptosis 
 
Caspase-2 is activated during apoptosis by a variety of apoptotic stimuli, including 
CD95L, TNFα, growth factor withdrawal and DNA damaging agents (Harvey et al., 
1997; Droin et al., 2001; Robertson et al., 2002; Stefanis et al., 1998). Although 
caspase-2 is classified as initiator caspase due to its long prodomain, the hierachical 
collocation within the caspase cascade is discussed controversially. For instance, 
caspase-2 is related to TNF receptor 1 (TNFR1) as well as CD95 death signalling due to 
its recruitment to these receptors mediated by the adaptor molecule RAIDD (Duan and 
Dixit, 2002). Involvement in the CD95-mediated pathway is additionally implicated by 
the contribution of caspase-2 to caspase-8 activation (Droin et al., 2001). In contrast, 
some studies query that caspase-2 plays a major role as initiator caspase by showing 
that Apaf-1 together with caspase-9 (O'Reilly et al., 2002) or the effector caspase-3 
(Paroni et al., 2001; Li et al., 1997; Slee et al., 1999) are required for the activation of 
caspase-2. These different observations may mainly reflect a cell-type and stimulus 
dependent manner of caspase-2 activation. Subcellular fractionation studies revealed 
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that procaspase-2 is present in several intracellular compartments, including cytosol, 
Golgi,  mitochondria and the nucleus (Susin et al., 1999; Mancini et al., 2000; Paroni et 
al., 2002; Zhivotovsky et al., 1999). Colussi and coworker (Colussi et al., 1998) were 
the first to show the presence of nuclear localisation sequences in certain regions of the 
prodomain of caspase-2 that regulate its nuclear import. In the following, Paroni and 
colleagues (Paroni et al., 2002) additionally demonstrated that caspase-2 can trigger 
mitochondrial dysfunction without relocalising into the cytoplasm. Furthermore, nuclear 
localisation of the caspase-2 adapter molecule RAIDD was observed (Shearwin-Whyatt 
et al., 2000). Interestingly, a very recent report showed that the cell cycle nuclear 
protein cyclin D3 interacts with and activates caspase-2 (Mendelsohn et al., 2002). 
Thus, it might be conceivable that drugs affecting the nucleus may lead to the activation 
of caspase-2 and subsequent mitochondrial cell death.  
Indeed, the present data show early activation of caspase-2 in ascididemin treated Jurkat 
T cells. The findings that the specific caspase-2 inhibitor zVDVAD-fmk was able to 
abolish DNA fragmentation clearly indicate the significant role of caspase-2 in the 
apoptotic signal transduction triggered by ascididemin. Studies with Bcl-xL 
overexpressing Jurkat T cells provide evidence that, in fact, processing of procaspase-2 
occurs upstream of mitochondria. Further activation of caspase-2 results from an 
amplification within the caspase cascade, which is a common event during the apoptotic 
process, as processing of procaspase-2 was reduced by the broadspectrum caspase 
inhibitor zVAD-fmk. Most importantly, caspase activity studies revealed that caspase-2 
is the most apical caspase in the ascididemin-induced caspase cascade.  
Very recently, Robertson et al. reported that activated caspase-2 acts upstream of 
mitochondria to regulate cytochorme c release following etoposide treatment 
(Robertson et al., 2002). The present results demonstrate that activated caspase-2, 
indeed, interferes with the mitochondrial pathway. Activated caspase-2 is required for 
mitochondrial cytochrome c release and subsequent processing of caspase-9 in response 
to ascididemin treatment.  
In vitro studies showed that recombinant caspase-2 can cleave Bid. Cleaved Bid in turn 
translocates to the mitochondria causing mitochondrial dysfunction (Paroni et al., 
2001). So far nothing is known about the signal transduction of activated caspase-2 to 
mitochondria via truncated Bid mediated by anticancer drugs. Concerning etoposide, 
the results of Robertson et al. suggest that active caspase-2 targets mitochondria and 
stimulates the release of cytochrome c without the requirement of Bid. In addition, 
purified caspase-2 can directly induce the release of apoptogenic factors from 
mitochondria (Guo et al., 2002). Surprisingly, Bid cleavage in Jurakt T cells exposed to 
ascididemin could be attenuated by the specific caspase-2 inhibitor zVDVAD-fmk. 
These data indicate that activated caspase-2 is able to cleave Bid in response to 
ascididemin. Thus, it is suggested that Bid links activated caspase-2 and mitochondrial 
dysfunction in the apoptotic process of ascididemin. 
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6 ROS and the apoptotic pathway mediated by ascididemin 
 
A critical role for oxidativ stress in the induction of apoptosis is provided, on the one 
hand, by studies which show that low levels of reactive oxygen species (ROS) induce 
apoptosis (Dumont et al., 1999) and, on the other hand, by the observation that various 
antioxidants, such as N-acetylcysteine (NAC) are able to inhibit apoptotic cell death 
(Dirsch et al., 1998; Friesen et al., 1999; Verhaegen et al., 1995). Additionally, ROS 
generation has been reported to occur in CD95-mediated apoptosis (Suzuki et al., 1998) 
as well as following exposure to UV irradiation (Gorman et al., 1997a) and 
chemotherapeutic drugs (Creagh and Cotter, 1999). In contrast, some reports 
demonstrate a rather contributory role of oxidative stress for the induction of apoptosis 
(Gorman et al., 1997a). Sentürker et al. even showed that chemotherapeutic drugs are 
able to trigger apoptosis without generation of ROS (Senturker et al., 2002). The results 
of the present work show that treatment of Jurkat T cells with ascididemin leads to a 
very early generation of ROS. However, oxidative stress does not play a major role in 
the apoptotic process as NAC did not affect DNA fragmentation. Nevertheless, ROS 
might be considered as a contributory factor to the initiation of ascididemin-induced 
apoptosis. Taking into account that DNA fragmentation appears at late stages of 
apoptosis the inhibitory effect of NAC may be overcome by parallel signalling 
pathways. Furthermore, in respect of the JNK pathway, the present results point to some 
impact of ROS in ascididemin-induced signalling (see 4.7). 
 
 
7 The role of MAPK and Akt in ascididemin-triggered apoptosis 
 
Signal transduction pathways involving the mitogen-activated protein kinases (MAPK) 
including the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK), the 
p38 MAPK and the extracellular signal-regulated kinases (Erk), have been shown to 
differentially contribute to pro- and antiapoptotic pathways. Erk are mainly activated by 
growth factors and mitogenic stimuli and pivotally linked to cell survival and 
mitogenesis (Chang and Karin, 2001). JNK and p38, on the other hand, are activated by 
a diverse array of cellular stresses, including ionising irradiation, ROS and cytotoxic 
agents, and either have been associated with apoptosis (Ortiz et al., 2001; Xia et al., 
1995; Zanke et al., 1996; Deschesnes et al., 2001).  
The results of the present work demonstrate that ascididemin induces the activation of 
JNK and p38 but not the activation of Erk.  
Although the activation of p38 is a very early event in the signalling triggered by 
ascididemin, the inhibition of the catalytic activity by the specific p38 inhibitor 
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SB203580 did not attenuate apoptosis. These results negate a significant impact of p38 
on the apoptotic process mediated by ascididemin. 
Inhibitory studies with the specific JNK inhibitor SP600125 demonstrated the causal 
involvement of activated JNK in the programmed cell death signalling induced by 
ascididemin. The fact that SP600125 only partially reduced the rate of apoptotic cells 
points out that the apoptotic response of Jurkat T cells to ascididemin does not solely 
derive from the JNK cascade. The present data show that JNK is activated 
independently of active caspases upstream of mitochondria as neither the 
broadspectrum caspase inhibitor zVAD-fmk nor overexpression of Bcl-xL and Bcl-2, 
respectively, could abrogate the phosphorylation of JNK (MacFarlane et al., 2000; 
Cahill et al., 1996; Srivastava et al., 1999). ROS could be identified as initial mediator 
of JNK activation as the antioxidant NAC prevented this process at early time points 
(Shiah et al., 1999). In accordance with reports of mitochondria as targets of JNK as 
well as requirement of JNK for cytochrome c release (Kharbanda et al., 2000; Aoki et 
al., 2002; Tournier et al., 2000), it is proven that active JNK contributes to ascididemin-
induced mitochondrial dysfunction: the translocation of cytochrome c from the 
mitochondria into the cytoplasm and the subsequent activation of caspase-9 is 
diminished in the presence of SP600125. However, Bcl-2 as direct target of JNK can be 
excluded (Maundrell et al., 1997). Taking into account that inhibition of active JNK 
only partially reduces the processing of the initiator caspase-2, a parallel activation of 
the caspase cascade is hypothesised. In conclusion, the results support the view that the 
redox sensitive activation of JNK contributes to the induction of the apoptotic process. 
Upon further progression, parallel signalling pathways, such as the caspase cascade 
followed by mitochondrial amplification, exceed the outcome of the JNK cascade.  
 
Several studies clearly demonstrated the survivial functions of Akt in the apoptotic 
process (Datta et al., 1999; del Peso et al., 1997; Cardone et al., 1998). Inhibition of Akt 
significantly increased the susceptibility of cells to chemotherapeutic- and CD95-
induced apoptosis (Tang et al., 2001; O'Gorman et al., 2001). However, the rate of 
ascididemin-triggered apoptosis was not altered in response to the inhibition of Akt 
activation by the PI3-kinase inhibitor wortmannin. This observation indicates that cell 
death signals predominate in the cellular response to ascididemin.  
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G. Summary 
The present work characterises the apoptotic signal transduction mediated by the marine 
pyridoacridine alkaloid ascididemin (5 µM) in human leukemia Jurkat T cells (fig. 56). 
Ascididemin was shown to induce apoptosis via a signalling cascade strongly dependent 
on the activation of caspases and mitochondrial dysfunction, but independent of CD95 
receptor signalling. 
In particular, caspase-2 was identified not only to be the most apical caspase of the 
caspase cascade but also to be essential for the apoptotic process triggered by 
ascididemin. Furthermore, it could be shown that caspase-2-mediated cleavage of Bid 
represents a possible link between active caspase-2 and mitochondrial perturbation in 
response to ascididemin. These results demonstrate a central role of caspase-2 in 
mitochondria-mediated signal transduction. This represents a new aspect of a 
mitochondria-dependent pathway. 
Ascididemin-induced mitochondrial dysfunction was demonstrated to be associated 
with the release of cytochrome c from the intermembrane space to the cytosol and the 
loss of the mitochondrial transmembrane potential.  
It was further shown that ascididemin triggers the redox-sensitive activation of JNK. A 
contributory role of active JNK to the induction of mitochondrial dysfunction and 
subsequent apoptosis in response to ascididemin could be verified. 
In summary, this thesis contributes to the understanding of the molecular mechanism 
regulating ascididemin-mediated apoptotic cell death in human leukemia Jurkat T cells. 
The anti-leukemic potential of ascididemin might be useful especially in the treatment 
of cells with low chemosensitivity caused by resistance in CD95 signalling. 
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Figure 56: Schematic illustration of the postulated signalling pathway induced by ascididemin.          
Since ascididemin is characterised as a DNA intercalating agent, it is proposed that the 
apoptotic signal arises from the nucleus. The signalling pathway is transduced by activation of 
caspase-2 and JNK, routed via mitochondria, amplified by the caspase cascade and finally 
targets a variety of death substrates. Signal transduction via the CD95 receptor is not 
involved. 
 
 
 
 
 
 
This work was supported by the DFG, SFB 369 (B7).         
 
H.  Bibliography 85 
H. Bibliography 
 
Alessi DR, James S R, Downes C P, Holmes A B, Gaffney P R, Reese C B and Cohen P (1997) 
Characterization of a 3-Phosphoinositide-Dependent Protein Kinase Which Phosphorylates and 
Activates Protein Kinase Balpha. Curr Biol 7: pp 261-269. 
Aoki H, Kang P M, Hampe J, Yoshimura K, Noma T, Matsuzaki M and Izumo S (2002) Direct 
Activation of Mitochondrial Apoptosis Machinery by C-Jun N-Terminal Kinase in Adult Cardiac 
Myocytes. J Biol Chem 277: pp 10244-10250. 
Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger T A and Schwarz T (1998) Ultraviolet 
Light Induces Apoptosis Via Direct Activation of CD95 (Fas/APO-1) Independently of Its Ligand 
CD95L. J Cell Biol 140: pp 171-182. 
Ashkenazi A and Dixit V M (1998) Death Receptors: Signaling and Modulation. Science 281: pp 1305-
1308. 
Ashkenazi A, Pai R C, Fong S, Leung S, Lawrence D A, Marsters S A, Blackie C, Chang L, McMurtrey 
A E, Hebert A, DeForge L, Koumenis I L, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z 
and Schwall R H (1999) Safety and Antitumor Activity of Recombinant Soluble Apo2 Ligand. J 
Clin Invest 104: pp 155-162. 
Banno Y., Wang S., Ito Y., Izumi T., Nakashima S., Shimizu T. and Nozawa Y. (2001) Involvement of 
ERK and P38 MAP Kinase in Oxidative Stress-Induced Phospholipase D Activation in PC12 
Cells. Neuroreport 12: pp 2271-2275. 
Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S and Schulze-Osthoff K (1998) Role of Reactive 
Oxygen Intermediates in Activation-Induced CD95 (APO-1/Fas) Ligand Expression. J Biol Chem 
273: pp 8048-8055. 
Becerro MA, Turon X and Uriz M J (1997) Multiple Functions for Secondary Metabolites in Encrusting 
Marine Invertebrates. J Chem Ecol 23: pp 1527-1547. 
Bennett BL, Sasaki D T, Murray B W, O'Leary E C, Sakata S T, Xu W, Leisten J C, Motiwala A, Pierce 
S, Satoh Y, Bhagwat S S, Manning A M and Anderson D W (2001) SP600125, an 
Anthrapyrazolone Inhibitor of Jun N-Terminal Kinase. Proc Natl Acad Sci U S A 98: pp 13681-
13686. 
Bernardi P, Scorrano L, Colonna R, Petronilli V and Di Lisa F (1999) Mitochondria and Cell Death. 
Mechanistic Aspects and Methodological Issues. Eur J Biochem 264: pp 687-701. 
Bertin J, Armstrong R C, Ottilie S, Martin D A, Wang Y, Banks S, Wang G H, Senkevich T G, Alnemri 
E S, Moss B, Lenardo M J, Tomaselli K J and Cohen J I (1997) Death Effector Domain-
Containing Herpesvirus and Poxvirus Proteins Inhibit Both Fas- and TNFR1-Induced Apoptosis. 
Proc Natl Acad Sci U S A 94: pp 1172-1176. 
H.  Bibliography 86 
Bonnard I, Bontemps N, Lahmy S, Banaigs B, Combaut G, Francisco C, Colson P, Houssier C, Waring 
M J and Bailly C (1995) Binding to DNA and Cytotoxic Evaluation of Ascididemin, the Major 
Alkaloid From the Mediterranean Ascidian Cystodytes Dellechiajei. Anticancer Drug Des 10: pp 
333-346. 
Bossy-Wetzel E, Newmeyer D D and Green D R (1998) Mitochondrial Cytochrome c Release in 
Apoptosis Occurs Upstream of DEVD- Specific Caspase Activation and Independently of 
Mitochondrial Transmembrane Depolarization. EMBO J 17: pp 37-49. 
Boulton TG, Nye S H, Robbins D J, Ip N Y, Radziejewska E, Morgenbesser S D, DePinho R A, 
Panayotatos N, Cobb M H and Yancopoulos G D (1991) ERKs: a Family of Protein-
Serine/Threonine Kinases That Are Activated and Tyrosine Phosphorylated in Response to Insulin 
and NGF. Cell 65: pp 663-675. 
Bracher F (1989) Total Synthesis of the Pentacyclic Alkaloid Ascididemin. Heterocycles 29: pp 2093-
2095. 
Bracher F (1992) Polycyclic Aromatic Alkaloids. 8. The Structure of Neocalliactine Acetate - Proof by 
Total Synthesis. Liebigs Ann Chem 11: pp 1205-1207. 
Bracher F (2002) Die Apotheke aus dem Meer. Einsichten 2: pp 34-38. Ref Type: Magazine Article 
 
Bradford M. (1976) A Rapid and Sensitive Method for the Quantification of Microgram Quantities of 
Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry 72: pp 248-254. 
Burow S and Valet G (1987) Flow-Cytometric Characterization of Stimulation, Free Radical Formation, 
Peroxidase Activity and Phagocytosis of Human Granulocytes With 2,7-Dichlorofluorescein 
(DCF). Eur J Cell Biol 43: pp 128-133. 
Burres NS, Sazesh S, Gunawardana G P and Clement J J (1989) Antitumor Activity and Nucleic Acid 
Binding Properties of Dercitin, a New Acridine Alkaloid Isolated From a Marine Dercitus Species 
Sponge. Cancer Res 49: pp 5267-5274. 
Buttke TM and Sandstrom P A (1994) Oxidative Stress As a Mediator of Apoptosis. Immunol Today 15: 
pp 7-10. 
Cahill MA, Peter M E, Kischkel F C, Chinnaiyan A M, Dixit V M, Krammer P H and Nordheim A 
(1996) CD95 (APO-1/Fas) Induces Activation of SAP Kinases Downstream of ICE-Like 
Proteases. Oncogene 13: pp 2087-2096. 
Cai J and Jones D P (1998) Superoxide in Apoptosis. Mitochondrial Generation Triggered by 
Cytochrome c Loss. J Biol Chem 273: pp 11401-11404. 
Capdeville R, Buchdunger E, Zimmermann J and Matter A (2002) Glivec (STI571, Imatinib), a 
Rationally Developed, Targeted Anticancer Drug. Nat Rev Drug Discov 1: pp 493-502. 
Cardone MH, Roy N, Stennicke H R, Salvesen G S, Franke T F, Stanbridge E, Frisch S and Reed J C 
(1998) Regulation of Cell Death Protease Caspase-9 by Phosphorylation. Science 282: pp 1318-
1321. 
Chang L and Karin M (2001) Mammalian MAP Kinase Signalling Cascades. Nature 410: pp 37-40. 
H.  Bibliography 87 
Chinnaiyan AM, Tepper C G, Seldin M F, O'Rourke K, Kischkel F C, Hellbardt S, Krammer P H, Peter 
M E and Dixit V M (1996) FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and 
Tumor Necrosis Factor Receptor-Induced Apoptosis. J Biol Chem 271: pp 4961-4965. 
Chlichlia K, Peter M E, Rocha M, Scaffidi C, Bucur M, Krammer P H, Schirrmacher V and Umansky V 
(1998) Caspase Activation Is Required for Nitric Oxide-Mediated, CD95(APO- 1/Fas)-Dependent 
and Independent Apoptosis in Human Neoplastic Lymphoid Cells. Blood 91: pp 4311-4320. 
Cobb MH and Goldsmith E J (1995) How MAP Kinases Are Regulated. J Biol Chem 270: pp 14843-
14846. 
Colussi PA, Harvey N L and Kumar S (1998) Prodomain-Dependent Nuclear Localization of the 
Caspase-2 (Nedd2) Precursor. A Novel Function for a Caspase Prodomain. J Biol Chem 273: pp 
24535-24542. 
Cossarizza A, Ceccarelli D and Masini A (1996) Functional Heterogeneity of an Isolated Mitochondrial 
Population Revealed by Cytofluorometric Analysis at the Single Organelle Level. Exp Cell Res 
222: pp 84-94. 
Cossarizza A, Franceschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A 
and Malorni W (1995) Protective Effect of N-Acetylcysteine in Tumor Necrosis Factor-Alpha-
Induced Apoptosis in U937 Cells: the Role of Mitochondria. Exp Cell Res 220: pp 232-240. 
Cotter TG, Lennon S V, Glynn J M and Green D R (1992) Microfilament-Disrupting Agents Prevent the 
Formation of Apoptotic Bodies in Tumor Cells Undergoing Apoptosis. Cancer Res 52: pp 997-
1005. 
Cragg GM, Newman D J and Snader K M (1997) Natural Products in Drug Discovery and Development. 
J Nat Prod 60: pp 52-60. 
Creagh EM and Cotter T G (1999) Selective Protection by Hsp 70 Against Cytotoxic Drug-, but Not Fas-
Induced T-Cell Apoptosis. Immunology 97: pp 36-44. 
Crompton M (1999) The Mitochondrial Permeability Transition Pore and Its Role in Cell Death. Biochem 
J 341 ( Pt 2): pp 233-249. 
Crook NE, Clem R J and Miller L K (1993) An Apoptosis-Inhibiting Baculovirus Gene With a Zinc 
Finger-Like Motif. J Virol 67: pp 2168-2174. 
Dassonneville L, Wattez N, Baldeyrou B, Mahieu C, Lansiaux A, Banaigs B, Bonnard I and Bailly C 
(2000) Inhibition of Topoisomerase II by the Marine Alkaloid Ascididemin and Induction of 
Apoptosis in Leukemia Cells. Biochem Pharmacol 60: pp 527-537. 
Datta SR, Brunet A and Greenberg M E (1999) Cellular Survival: a Play in Three Akts. Genes Dev 13: pp 
2905-2927. 
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg M E (1997) Akt Phosphorylation of 
BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. Cell 91: pp 231-241. 
Davis RJ (1993) The Mitogen-Activated Protein Kinase Signal Transduction Pathway. J Biol Chem 268: 
pp 14553-14556. 
H.  Bibliography 88 
Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R and Kroemer G (1997) Bcl-
2 and Bcl-XL Antagonize the Mitochondrial Dysfunction Preceding Nuclear Apoptosis Induced by 
Chemotherapeutic Agents. Cancer Res 57: pp 62-67. 
del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G (1997) Interleukin-3-Induced 
Phosphorylation of BAD Through the Protein Kinase Akt. Science 278: pp 687-689. 
Delfourne E, Darro F, Portefaix P, Galaup C, Bayssade S, Bouteille A, Le Corre L, Bastide J, Collignon 
F, Lesur B, Frydman A and Kiss R (2002) Synthesis and in Vitro Antitumor Activity of Novel 
Ring D Analogues of the Marine Pyridoacridine Ascididemin: Structure-Activity Relationship. J 
Med Chem 45: pp 3765-3771. 
Delneste Y, Jeannin P, Sebille E, Aubry J P and Bonnefoy J Y (1996) Thiols Prevent Fas (CD95)-
Mediated T Cell Apoptosis by Down-Regulating Membrane Fas Expression. Eur J Immunol 26: 
pp 2981-2988. 
Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and 
Martinou J C (1999) Bid-Induced Conformational Change of Bax Is Responsible for 
Mitochondrial Cytochrome c Release During Apoptosis. J Cell Biol 144: pp 891-901. 
Deschesnes RG, Huot J, Valerie K and Landry J (2001) Involvement of P38 in Apoptosis-Associated 
Membrane Blebbing and Nuclear Condensation. Mol Biol Cell 12: pp 1569-1582. 
Dhein J, Daniel P T, Trauth B C, Oehm A, Moller P and Krammer P H (1992) Induction of Apoptosis by 
Monoclonal Antibody Anti-APO-1 Class Switch Variants Is Dependent on Cross-Linking of APO-
1 Cell Surface Antigens. J Immunol 149: pp 3166-3173. 
Ding Q, Chichak K and Lown J W (1999) Pyrroloquinoline and Pyridoacridine Alkaloids From Marine 
Sources. Curr Med Chem 6: pp 1-27. 
Dirsch VM, Antlsperger D S, Hentze H and Vollmar A M (2002) Ajoene, an Experimental Anti-
Leukemic Drug: Mechanism of Cell Death. Leukemia 16: pp 74-83. 
Dirsch VM, Gerbes A L and Vollmar A M (1998) Ajoene, a Compound of Garlic, Induces Apoptosis in 
Human Promyeloleukemic Cells, Accompanied by Generation of Reactive Oxygen Species and 
Activation of Nuclear Factor KappaB. Mol Pharmacol 53: pp 402-407. 
Droge W (2002) Free Radicals in the Physiological Control of Cell Function. Physiol Rev 82: pp 47-95. 
Droin N, Bichat F, Rebe C, Wotawa A, Sordet O, Hammann A, Bertrand R and Solary E (2001) 
Involvement of Caspase-2 Long Isoform in Fas-Mediated Cell Death of Human Leukemic Cells. 
Blood 97: pp 1835-1844. 
Du C, Fang M, Li Y, Li L and Wang X (2000) Smac, a Mitochondrial Protein That Promotes Cytochrome 
C-Dependent Caspase Activation by Eliminating IAP Inhibition. Cell 102: pp 33-42. 
Duan H and Dixit V M (2002) RAIDD Is a New "Death" Adaptor Molecule. Nature 385: pp 86-89. 
Duckett CS, Nava V E, Gedrich R W, Clem R J, Van Dongen J L, Gilfillan M C, Shiels H, Hardwick J M 
and Thompson C B (1996) A Conserved Family of Cellular Genes Related to the Baculovirus Iap 
Gene and Encoding Apoptosis Inhibitors. EMBO J 15: pp 2685-2694. 
H.  Bibliography 89 
Dumont A, Hehner S P, Hofmann T G, Ueffing M, Droge W and Schmitz M L (1999) Hydrogen 
Peroxide-Induced Apoptosis Is CD95-Independent, Requires the Release of Mitochondria-Derived 
Reactive Oxygen Species and the Activation of NF-KappaB. Oncogene 18: pp 747-757. 
Duvall E, Wyllie A H and Morris R G (1985) Macrophage Recognition of Cells Undergoing Programmed 
Cell Death (Apoptosis). Immunology 56: pp 351-358. 
Earnshaw WC, Martins L M and Kaufmann S H (1999) Mammalian Caspases: Structure, Activation, 
Substrates, and Functions During Apoptosis. Annu Rev Biochem 68: pp 383-424. 
Eder C, Schupp P, Proksch P, Wray V, Steube K, Muller C E, Frobenius W, Herderich M and van Soest 
R W (1998) Bioactive Pyridoacridine Alkaloids From the Micronesian Sponge Oceanapia Sp. J 
Nat Prod 61: pp 301-305. 
Ehlert JE and Kubbutat M H (2001) Apoptosis and Its Relevance in Cancer Therapy. Onkologie 24: pp 
433-440. 
Eischen CM, Kottke T J, Martins L M, Basi G S, Tung J S, Earnshaw W C, Leibson P J and Kaufmann S 
H (1997) Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced 
Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. Blood 90: pp 935-943. 
Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke R U, Porter A G, 
Belka C, Gregor M, Schulze-Osthoff K and Wesselborg S (2000) Caspase-8/FLICE Functions As 
an Executioner Caspase in Anticancer Drug-Induced Apoptosis. Oncogene 19: pp 4563-4573. 
Fadok VA, Voelker D R, Campbell P A, Cohen J J, Bratton D L and Henson P M (1992) Exposure of 
Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and 
Removal by Macrophages. J Immunol 148: pp 2207-2216. 
Friesen C, Fulda S and Debatin K M (1999) Induction of CD95 Ligand and Apoptosis by Doxorubicin Is 
Modulated by the Redox State in Chemosensitive- and Drug-Resistant Tumor Cells. Cell Death 
Differ 6: pp 471-480. 
Friesen C, Herr I, Krammer P H and Debatin K M (1996) Involvement of the CD95 (APO-1/FAS) 
Receptor/Ligand System in Drug-Induced Apoptosis in Leukemia Cells. Nat Med 2: pp 574-577. 
Fujiwara T, Grimm E A, Mukhopadhyay T, Zhang W W, Owen-Schaub L B and Roth J A (1994) 
Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-Mediated 
Transfer of the Wild-Type P53 Gene. Cancer Res 54: pp 2287-2291. 
Fulda S, Strauss G, Meyer E and Debatin K M (2000) Functional CD95 Ligand and CD95 Death-
Inducing Signaling Complex in Activation-Induced Cell Death and Doxorubicin-Induced 
Apoptosis in Leukemic T Cells. Blood 95: pp 301-308. 
Gajate C, Fonteriz R I, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M and Mollinedo F 
(2000) Intracellular Triggering of Fas, Independently of FasL, As a New Mechanism of Antitumor 
Ether Lipid-Induced Apoptosis. Int J Cancer 85: pp 674-682. 
Gliniak B and Le T (1999) Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand's Antitumor 
Activity in Vivo Is Enhanced by the Chemotherapeutic Agent CPT-11. Cancer Res 59: pp 6153-
6158. 
H.  Bibliography 90 
Gorman A, McGowan A and Cotter T G (1997a) Role of Peroxide and Superoxide Anion During Tumour 
Cell Apoptosis. FEBS Lett 404: pp 27-33. 
Gorman AM, Samali A, McGowan A J and Cotter T G (1997b) Use of Flow Cytometry Techniques in 
Studying Mechanisms of Apoptosis in Leukemic Cells. Cytometry 29: pp 97-105. 
Grabley S and Thiericke R (1999) Drug Discovery From Nature. Springer Verlag. Ref Type: Book 
Griffith TS, Brunner T, Fletcher S M, Green D R and Ferguson T A (1995) Fas Ligand-Induced 
Apoptosis As a Mechanism of Immune Privilege. Science 270: pp 1189-1192. 
Gross A, Jockel J, Wei M C and Korsmeyer S J (1998) Enforced Dimerization of BAX Results in Its 
Translocation, Mitochondrial Dysfunction and Apoptosis. EMBO J 17: pp 3878-3885. 
Guo Y, Srinivasula S M, Druilhe A, Fernandes-Alnemri T and Alnemri E S (2002) Caspase-2 Induces 
Apoptosis by Releasing Proapoptotic Proteins From Mitochondria. J Biol Chem 277: pp 13430-
13437. 
Gurtu V, Kain S R and Zhang G (1997) Fluorometric and Colorimetric Detection of Caspase Activity 
Associated With Apoptosis. Anal Biochem 251: pp 98-102. 
Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French L E, Schneider P, Bornand T, Fontana 
A, Lienard D, Cerottini J and Tschopp J (1996) Melanoma Cell Expression of Fas(Apo-1/CD95) 
Ligand: Implications for Tumor Immune Escape. Science 274: pp 1363-1366. 
Haldar S, Jena N and Croce C M (1995) Inactivation of Bcl-2 by Phosphorylation. Proc Natl Acad Sci U 
S A 92: pp 4507-4511. 
Harvey NL, Butt A J and Kumar S (1997) Functional Activation of Nedd2/ICH-1 (Caspase-2) Is an Early 
Process in Apoptosis. J Biol Chem 272: pp 13134-13139. 
Hausler P, Papoff G, Eramo A, Reif K, Cantrell D A and Ruberti G (1998) Protection of CD95-Mediated 
Apoptosis by Activation of Phosphatidylinositide 3-Kinase and Protein Kinase B. Eur J Immunol 
28: pp 57-69. 
Hengartner MO (2000) The Biochemistry of Apoptosis. Nature 407: pp 770-776. 
Hengartner MO and Horvitz H R (1994) C. Elegans Cell Survival Gene Ced-9 Encodes a Functional 
Homolog of the Mammalian Proto-Oncogene Bcl-2. Cell 76: pp 665-676. 
Huang Y, Park Y C, Rich R L, Segal D, Myszka D G and Wu H (2001) Structural Basis of Caspase 
Inhibition by XIAP: Differential Roles of the Linker Versus the BIR Domain. Cell 104: pp 781-
790. 
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J L, Schroter M, Burns K, 
Mattmann C, Rimoldi D, French L E and Tschopp J (1997) Inhibition of Death Receptor Signals 
by Cellular FLIP [See Comments]. Nature 388: pp 190-195. 
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y and Nagata S 
(1991) The Polypeptide Encoded by the CDNA for Human Cell Surface Antigen Fas Can Mediate 
Apoptosis. Cell 66: pp 233-243. 
H.  Bibliography 91 
Jo M, Kim T H, Seol D W, Esplen J E, Dorko K, Billiar T R and Strom S C (2000) Apoptosis Induced in 
Normal Human Hepatocytes by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Nat 
Med 6: pp 564-567. 
Karin M (1995) The Regulation of AP-1 Activity by Mitogen-Activated Protein Kinases. J Biol Chem 
270: pp 16483-16486. 
Karpinich NO, Tafani M, Rothman R J, Russo M A and Farber J L (2002) The Course of Etoposide-
Induced Apoptosis From Damage to DNA and P53 Activation to Mitochondrial Release of 
Cytochrome c. J Biol Chem 277: pp 16547-16552. 
Kennedy SG, Wagner A J, Conzen S D, Jordan J, Bellacosa A, Tsichlis P N and Hay N (1997) The PI 3-
Kinase/Akt Signaling Pathway Delivers an Anti-Apoptotic Signal. Genes Dev 11: pp 701-713. 
Kerr JF, Wyllie A H and Currie A R (1972) Apoptosis: a Basic Biological Phenomenon With Wide-
Ranging Implications in Tissue Kinetics. Br J Cancer 26: pp 239-257. 
Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen Y N, Campbell A, 
Sudha T, Yuan Z M, Narula J, Weichselbaum R, Nalin C and Kufe D (2000) Translocation of 
SAPK/JNK to Mitochondria and Interaction With Bcl-x(L) in Response to DNA Damage. J Biol 
Chem 275: pp 322-327. 
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer P H and Peter M E (1995) 
Cytotoxicity-Dependent APO-1 (Fas/CD95)-Associated Proteins Form a Death-Inducing Signaling 
Complex (DISC) With the Receptor. EMBO J 14: pp 5579-5588. 
Kobayashi J, Cheng J, Nakamura Y, Ohizumi Y, Hirata Y, Sasaki T, Otha T and Nozoe S (1988a) 
Ascididemin, a Novel Pentacyclic Aromatic Alkaloid With Potent Antileukemic Activity From the 
Okinawan Tunicate Didemnum Sp. Tetrahedron Letters 29: pp 1177. 
Kobayashi J, Cheng J, Walchli M R, Nakamura H, Hirata Y, Sasaki T and Ohizumi Y (1988b) 
Cystodytins A, B, and C, Novel Tetracyclic Aromatic Alkaloids With Potent Antineoplastic 
Activity From the Okinawan Tunicate Cystodytes Dellechiajei. J Org Chem 53: pp 1800-1804. 
Krajewski S, Tanaka S, Takayama S, Schibler M J, Fenton W and Reed J C (1993) Investigation of the 
Subcellular Distribution of the Bcl-2 Oncoprotein: Residence in the Nuclear Envelope, 
Endoplasmic Reticulum, and Outer Mitochondrial Membranes. Cancer Res 53: pp 4701-4714. 
Krammer PH (2000) CD95's Deadly Mission in the Immune System. Nature 407: pp 789-795. 
Kroemer G, Dallaporta B and Resche-Rigon M (1998) The Mitochondrial Death/Life Regulator in 
Apoptosis and Necrosis. Annu Rev Physiol 60: pp 619-642. 
Kroemer G and Reed J C (2000) Mitochondrial Control of Cell Death. Nat Med 6: pp 513-519. 
Laemmli UK (1970) Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage 
T4. Nature 227: pp 680-685. 
Leist M, Volbracht C, Fava E and Nicotera P (1998) 1-Methyl-4-Phenylpyridinium Induces Autocrine 
Excitotoxicity Protease Activation, and Neuronal Apoptosis. Mol Pharmacol 54: pp 789-801. 
 
H.  Bibliography 92 
Lenczowski JM, Dominguez L, Eder A M, King L B, Zacharchuk C M and Ashwell J D (1997) Lack of a 
Role for Jun Kinase and AP-1 in Fas-Induced Apoptosis. Mol Cell Biol 17: pp 170-181. 
Li H, Bergeron L, Cryns V, Pasternack M S, Zhu H, Shi L, Greenberg A and Yuan J (1997) Activation of 
Caspase-2 in Apoptosis. J Biol Chem 272: pp 21010-21017. 
Li YQ, Hii C S, Der C J and Ferrante A (1999) Direct Evidence That ERK Regulates the 
Production/Secretion of Interleukin-2 in PHA/PMA-Stimulated T Lymphocytes. Immunology 96: 
pp 524-528. 
Lindsay BS, Barrows L R and Copp B R (1995) Structural Requirements for Biological Activity of the 
Marine Alkaloid Ascididemin. Bioorganic & Medicinal Chemistry Letters 5: pp 739-742. 
Lindsay BS, Pearce A N and Copp B R (1997) Efficient and Convenient Pyridine Ring-e Formation of 
the Cytotoxic Marine Alkaloid Ascididemin and Related Analogs. Synthetic communications 27: 
pp 2587-2592. 
Lorenzo HK, Susin S A, Penninger J and Kroemer G (1999) Apoptosis Inducing Factor (AIF): a 
Phylogenetically Old, Caspase-Independent Effector of Cell Death. Cell Death Differ 6: pp 516-
524. 
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X (1998) Bid, a Bcl2 Interacting Protein, Mediates 
Cytochrome c Release From Mitochondria in Response to Activation of Cell Surface Death 
Receptors. Cell 94: pp 481-490. 
MacFarlane M, Cohen G M and Dickens M (2000) JNK (c-Jun N-Terminal Kinase) and P38 Activation 
in Receptor-Mediated and Chemically-Induced Apoptosis of T-Cells: Differential Requirements 
for Caspase Activation. Biochem J 348 Pt 1: pp 93-101. 
Mancini M, Machamer C E, Roy S, Nicholson D W, Thornberry N A, Casciola-Rosen L A and Rosen A 
(2000) Caspase-2 Is Localized at the Golgi Complex and Cleaves Golgin-160 During Apoptosis. J 
Cell Biol 149: pp 603-612. 
Martin SJ, Finucane D M, Amarante-Mendes G P, O'Brien G A and Green D R (1996) 
Phosphatidylserine Externalization During CD95-Induced Apoptosis of Cells and Cytoplasts 
Requires ICE/CED-3 Protease Activity. J Biol Chem 271: pp 28753-28756. 
Martinou JC and Green D R (2001) Breaking the Mitochondrial Barrier. Nat Rev Mol Cell Biol 2: pp 63-
67. 
Mashima T, Naito M and Tsuruo T (1999) Caspase-Mediated Cleavage of Cytoskeletal Actin Plays a 
Positive Role in the Process of Morphological Apoptosis. Oncogene 18: pp 2423-2430. 
Mathiasen IS, Lademann U and Jaattela M (1999) Apoptosis Induced by Vitamin D Compounds in Breast 
Cancer Cells Is Inhibited by Bcl-2 but Does Not Involve Known Caspases or P53. Cancer Res 59: 
pp 4848-4856. 
Matsumoto SS, Sidford M H, Holden J A, Barrows L R and Copp B R (2000) Mechanism of Action 
Studies of Cytotoxic Marine Alkaloids: Ascididemin Exhibits Thiol-Dependent Oxidative DNA 
Cleavage. Tetrahedron Letters 41: pp 1667-1670. 
H.  Bibliography 93 
Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-
Knecht E, Martinou J C and Arkinstall S (1997) Bcl-2 Undergoes Phosphorylation by C-Jun N-
Terminal Kinase/Stress-Activated Protein Kinases in the Presence of the Constitutively Active 
GTP-Binding Protein Rac1. J Biol Chem 272: pp 25238-25242. 
McDonald LA, Eldredge G S, Barrows L R and Ireland C M (1994) Inhibition of Topoisomerase II 
Catalytic Activity by Pyridoacridine Alkaloids From a Cystodytes Sp. Ascidian: a Mechanism for 
the Apparent Intercalator-Induced Inhibition of Topoisomerase II. J Med Chem 37: pp 3819-3827. 
McGahon AJ, Costa Pereira A P, Daly L and Cotter T G (1998) Chemotherapeutic Drug-Induced 
Apoptosis in Human Leukaemic Cells Is Independent of the Fas (APO-1/CD95) Receptor/Ligand 
System. Br J Haematol 101: pp 539-547. 
McGowan AJ, Ruiz-Ruiz M C, Gorman A M, Lopez-Rivas A and Cotter T G (1996) Reactive Oxygen 
Intermediate(s) (ROI): Common Mediator(s) of Poly(ADP-Ribose)Polymerase (PARP) Cleavage 
and Apoptosis. FEBS Lett 392: pp 299-303. 
Meier P, Finch A and Evan G (2000) Apoptosis in Development. Nature 407: pp 796-801. 
Mendelsohn AR, Hamer J D, Wang Z B and Brent R (2002) Cyclin D3 Activates Caspase 2, Connecting 
Cell Proliferation With Cell Death. Proc Natl Acad Sci U S A 99: pp 6871-6876. 
Micheau O, Solary E, Hammann A and Dimanche-Boitrel M T (1999) Fas Ligand-Independent, FADD-
Mediated Activation of the Fas Death Pathway by Anticancer Drugs. J Biol Chem 274: pp 7987-
7992. 
Micheau O, Solary E, Hammann A, Martin F and Dimanche-Boitrel M T (1997) Sensitization of Cancer 
Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity. J Natl Cancer Inst 89: pp 783-
789. 
Mildner M, Eckhart L, Lengauer B and Tschachler E (2002) Hepatocyte Growth Factor/Scatter Factor 
Inhibits UVB-Induced Apoptosis of Human Keratinocytes but Not of Keratinocyte-Derived Cell 
Lines Via the Phosphatidylinositol 3-Kinase/AKT Pathway. J Biol Chem 277: pp 14146-14152. 
Mitsiades N, Yu W H, Poulaki V, Tsokos M and Stamenkovic I (2001) Matrix Metalloproteinase-7-
Mediated Cleavage of Fas Ligand Protects Tumor Cells From Chemotherapeutic Drug 
Cytotoxicity. Cancer Res 61: pp 577-581. 
Mo YY and Beck W T (1999) DNA Damage Signals Induction of Fas Ligand in Tumor Cells. Mol 
Pharmacol 55: pp 216-222. 
Molinski TF (1993) Marine Pyridoacridine Alkaloids: Structure, Synthesis, and Biological Chemistry. 
Chemical Reviews 93: pp 1825-1838. 
Morel F, Doussiere J and Vignais P V (1991) The Superoxide-Generating Oxidase of Phagocytic Cells. 
Physiological, Molecular and Pathological Aspects. Eur J Biochem 201: pp 523-546. 
Mosmann T (1983) Rapid Colorimetric Assay for Cellular Growth and Survival: Application to 
Proliferation and Cytotoxicity Assays. J Immunol Methods 65: pp 55-63. 
Muzio M, Chinnaiyan A M, Kischkel F C, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz J D, Zhang 
M, Gentz R, Mann M, Krammer P H, Peter M E and Dixit V M (1996) FLICE, a Novel FADD-
H.  Bibliography 94 
Homologous ICE/CED-3-Like Protease, Is Recruited to the CD95 (Fas/APO-1) Death--Inducing 
Signaling Complex. Cell 85: pp 817-827. 
Nagata S and Golstein P (1995) The Fas Death Factor. Science 267: pp 1449-1456. 
Nicholson DW (2000) From Bench to Clinic With Apoptosis-Based Therapeutic Agents. Nature 407: pp 
810-816. 
Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F and Jaattela M (2000) Selective Depletion of 
Heat Shock Protein 70 (Hsp70) Activates a Tumor-Specific Death Program That Is Independent of 
Caspases and Bypasses Bcl-2. Proc Natl Acad Sci U S A 97: pp 7871-7876. 
O'Gorman DM, McKenna S L, McGahon A J and Cotter T G (2001) Inhibition of PI3-Kinase Sensitises 
HL60 Human Leukaemia Cells to Both Chemotherapeutic Drug- and Fas-Induced Apoptosis by a 
JNK Independent Pathway. Leuk Res 25: pp 801-811. 
O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux D L, Hacker G, Magnusson C, Pakusch M, 
Cecconi F, Kuida K, Strasser A, Huang D C and Kumar S (2002) Caspase-2 Is Not Required for 
Thymocyte or Neuronal Apoptosis Even Though Cleavage of Caspase-2 Is Dependent on Both 
Apaf-1 and Caspase-9. Cell Death Differ 9: pp 832-841. 
Oltvai ZN, Milliman C L and Korsmeyer S J (1993) Bcl-2 Heterodimerizes in Vivo With a Conserved 
Homolog, Bax, That Accelerates Programmed Cell Death. Cell 74: pp 609-619. 
Orlinick JR, Vaishnaw A, Elkon K B and Chao M V (1997) Requirement of Cysteine-Rich Repeats of the 
Fas Receptor for Binding by the Fas Ligand. J Biol Chem 272: pp 28889-28894. 
Ortiz MA, Lopez-Hernandez F J, Bayon Y, Pfahl M and Piedrafita F J (2001) Retinoid-Related 
Molecules Induce Cytochrome c Release and Apoptosis Through Activation of C-Jun NH(2)-
Terminal Kinase/P38 Mitogen-Activated Protein Kinases. Cancer Res 61: pp 8504-8512. 
Ottilie S, Diaz J L, Horne W, Chang J, Wang Y, Wilson G, Chang S, Weeks S, Fritz L C and Oltersdorf T 
(1997) Dimerization Properties of Human BAD. Identification of a BH-3 Domain and Analysis of 
Its Binding to Mutant BCL-2 and BCL-XL Proteins. J Biol Chem 272: pp 30866-30872. 
Panka DJ, Mano T, Suhara T, Walsh K and Mier J W (2001) Phosphatidylinositol 3-Kinase/Akt Activity 
Regulates C-FLIP Expression in Tumor Cells. J Biol Chem 276: pp 6893-6896. 
Park J, Kim I, Oh Y J, Lee K, Han P L and Choi E J (1997) Activation of C-Jun N-Terminal Kinase 
Antagonizes an Anti-Apoptotic Action of Bcl-2. J Biol Chem 272: pp 16725-16728. 
Paroni G, Henderson C, Schneider C and Brancolini C (2001) Caspase-2-Induced Apoptosis Is 
Dependent on Caspase-9, but Its Processing During UV- or Tumor Necrosis Factor-Dependent 
Cell Death Requires Caspase-3. J Biol Chem 276: pp 21907-21915. 
Paroni G, Henderson C, Schneider C and Brancolini C (2002) Caspase-2 Can Trigger Cytochrome C 
Release and Apoptosis From the Nucleus. J Biol Chem 277: pp 15147-15161. 
Pawlik JR (1993) Marine Invertebrate Chemical Defenses. Chem Rev 93: pp 1911-1922. 
H.  Bibliography 95 
Peter ME, Dhein J, Ehret A, Hellbardt S, Walczak H, Moldenhauer G and Krammer P H (1995) APO-1 
(CD95)-Dependent and -Independent Antigen Receptor-Induced Apoptosis in Human T and B 
Cell Lines. Int Immunol 7: pp 1873-1877. 
Reed JC (1998) Bcl-2 Family Proteins. Oncogene 17: pp 3225-3236. 
Roberts LR, Adjei P N and Gores G J (1999) Cathepsins As Effector Proteases in Hepatocyte Apoptosis. 
Cell Biochem Biophys 30: pp 71-88. 
Robertson JD, Enoksson M, Suomela M, Zhivotovsky B and Orrenius S (2002) Caspase-2 Acts Upstream 
of Mitochondria to Promote Cytochrome c Release During Etoposide-Induced Apoptosis. J Biol 
Chem 277: pp 29803-29809. 
Robertson JD, Gogvadze V, Zhivotovsky B and Orrenius S (2000) Distinct Pathways for Stimulation of 
Cytochrome c Release by Etoposide. J Biol Chem 275: pp 32438-32443. 
Rottmayer, Eva-Maria (2001) Licht- und elektronenmikroskopische Untersuchungen der Tunika von 
Cystodytes dellechiajei DELLA VALLE (Urochordata, Ascidiacea). Ref Type: Thesis/Dissertation 
 
Rowley JD (1973) Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous 
Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature 243: pp 290-293. 
Sakahira H, Enari M and Nagata S (1998) Cleavage of CAD Inhibitor in CAD Activation and DNA 
Degradation During Apoptosis. Nature 391: pp 96-99. 
Saleh A, Srinivasula S M, Acharya S, Fishel R and Alnemri E S (1999) Cytochrome c and DATP-
Mediated Oligomerization of Apaf-1 Is a Prerequisite for Procaspase-9 Activation. J Biol Chem 
274: pp 17941-17945. 
Salvesen GS and Dixit V M (1999) Caspase Activation: the Induced-Proximity Model. Proc Natl Acad 
Sci U S A 96: pp 10964-10967. 
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli K J, Debatin K M, Krammer P H and Peter 
M E (1998) Two CD95 (APO-1/Fas) Signaling Pathways. EMBO J 17: pp 1675-1687. 
Schmitt CA and Lowe S W (1999) Apoptosis and Therapy. J Pathol 187: pp 127-137. 
Schmitz FJ, Agarwal S K, Gunasekera S P, Schmidt P G and Shoolery J N (1983) Amphimedine, New 
Aromatic Alkaloid From a Pacific Sponge, Amphimedon Sp. Carbon Connectivity Determination 
From Natural Abundance Carbon-13-Carbon-13 Coupling Constants. J Am Chem Soc 105: pp 
4835-4836. 
Schmitz FJ, DeGuzman F S, Hossain M B and van der Helm D (1991) Cytotoxic Aromatic Alkaloids 
From the Ascidian Amphicarpa Meridiana and Leptoclinides Sp.: Meridine and 11-
Hydroxyascididemin. Journal of Organic Chemistry 56: pp 804-808. 
Schreck R, Rieber P and Baeuerle P A (1991) Reactive Oxygen Intermediates As Apparently Widely 
Used Messengers in the Activation of the NF-Kappa B Transcription Factor and HIV-1. EMBO J 
10: pp 2247-2258. 
H.  Bibliography 96 
Schwartsmann G, Brondani d R, Berlinck R G and Jimeno J (2001) Marine Organisms As a Source of 
New Anticancer Agents. Lancet Oncol 2: pp 221-225. 
Schwartsmann G, Ratain M J, Cragg G M, Wong J E, Saijo N, Parkinson D R, Fujiwara Y, Pazdur R, 
Newman D J, Dagher R and Di Leone L (2002) Anticancer Drug Discovery and Development 
Throughout the World. J Clin Oncol 20: pp 47S-59S. 
Senturker S, Tschirret-Guth R, Morrow J, Levine R and Shacter E (2002) Induction of Apoptosis by 
Chemotherapeutic Drugs Without Generation of Reactive Oxygen Species. Arch Biochem Biophys 
397: pp 262-272. 
Shearwin-Whyatt LM, Harvey N L and Kumar S (2000) Subcellular Localization and CARD-Dependent 
Oligomerization of the Death Adaptor RAIDD. Cell Death Differ 7: pp 155-165. 
Shiah SG, Chuang S E, Chau Y P, Shen S C and Kuo M L (1999) Activation of C-Jun NH2-Terminal 
Kinase and Subsequent CPP32/Yama During Topoisomerase Inhibitor Beta-Lapachone-Induced 
Apoptosis Through an Oxidation-Dependent Pathway. Cancer Res 59: pp 391-398. 
Shimizu S, Narita M and Tsujimoto Y (1999) Bcl-2 Family Proteins Regulate the Release of Apoptogenic 
Cytochrome c by the Mitochondrial Channel VDAC. Nature 399: pp 483-487. 
Siitonen T, Mantymaa P, Saily M, Savolainen E and Koistinen P (2000) Etoposide-Induced Apoptosis Is 
Not Associated With the Fas Pathway in Acute Myeloblastic Leukemia Cells. Leuk Res 24: pp 
281-288. 
Slee EA, Harte M T, Kluck R M, Wolf B B, Casiano C A, Newmeyer D D, Wang H G, Reed J C, 
Nicholson D W, Alnemri E S, Green D R and Martin S J (1999) Ordering the Cytochrome C-
Initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a 
Caspase-9- Dependent Manner. J Cell Biol 144: pp 281-292. 
Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee R A, Robbins P D, Fernandes-
Alnemri T, Shi Y and Alnemri E S (2001) A Conserved XIAP-Interaction Motif in Caspase-9 and 
Smac/DIABLO Regulates Caspase Activity and Apoptosis. Nature 410: pp 112-116. 
Srivastava RK, Sollott S J, Khan L, Hansford R, Lakatta E G and Longo D L (1999) Bcl-2 and Bcl-X(L) 
Block Thapsigargin-Induced Nitric Oxide Generation, C-Jun NH(2)-Terminal Kinase Activity, and 
Apoptosis. Mol Cell Biol 19: pp 5659-5674. 
Stefanis L, Troy C M, Qi H, Shelanski M L and Greene L A (1998) Caspase-2 (Nedd-2) Processing and 
Death of Trophic Factor-Deprived PC12 Cells and Sympathetic Neurons Occur Independently of 
Caspase-3 (CPP32)-Like Activity. J Neurosci 18: pp 9204-9215. 
Steffan B, Brix K and Pütz W (1993) Biosynthesis of Shermilamine B. Tetrahedron 49: pp 6223-6228. 
Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K and Nagata S (1995) Expression of the 
Fas Ligand in Cells of T Cell Lineage. J Immunol 154: pp 3806-3813. 
Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular Cloning and Expression of the Fas 
Ligand, a Novel Member of the Tumor Necrosis Factor Family. Cell 75: pp 1169-1178. 
H.  Bibliography 97 
Susin SA, Lorenzo H K, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost M C, Alzari P M and 
Kroemer G (1999) Mitochondrial Release of Caspase-2 and -9 During the Apoptotic Process. J 
Exp Med 189: pp 381-394. 
Suzuki Y, Ono Y and Hirabayashi Y (1998) Rapid and Specific Reactive Oxygen Species Generation Via 
NADPH Oxidase Activation During Fas-Mediated Apoptosis. FEBS Lett 425: pp 209-212. 
Takahashi A, Alnemri E S, Lazebnik Y A, Fernandes-Alnemri T, Litwack G, Moir R D, Goldman R D, 
Poirier G G, Kaufmann S H and Earnshaw W C (1996) Cleavage of Lamin A by Mch2 Alpha but 
Not CPP32: Multiple Interleukin 1 Beta-Converting Enzyme-Related Proteases With Distinct 
Substrate Recognition Properties Are Active in Apoptosis. Proc Natl Acad Sci U S A 93: pp 8395-
8400. 
Takahashi A and Earnshaw W C (1996) ICE-Related Proteases in Apoptosis. Curr Opin Genet Dev 6: pp 
50-55. 
Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak T W and Ingram A J (2001) Akt Is Activated in 
Response to an Apoptotic Signal. J Biol Chem 276: pp 30461-30466. 
Taraporewala IB, Cessac J W, Chanh T C, Delgado A V and Schinazi R F (1992) HIV-1 Neutralization 
and Tumor Cell Proliferation Inhibition in Vitro by Simplified Analogues of Pyrido[4,3,2-
Mn]Thiazolo[5,4-b]Acridine Marine Alkaloids. J Med Chem 35: pp 2744-2752. 
Thornberry NA, Rano T A, Peterson E P, Rasper D M, Timkey T, Garcia-Calvo M, Houtzager V M, 
Nordstrom P A, Roy S, Vaillancourt J P, Chapman K T and Nicholson D W (1997) A 
Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme 
B. Functional Relationships Established for Key Mediators of Apoptosis. J Biol Chem 272: pp 
17907-17911. 
Toker A and Newton A C (2000) Akt/Protein Kinase B Is Regulated by Autophosphorylation at the 
Hypothetical PDK-2 Site. J Biol Chem 275: pp 8271-8274. 
Tournier C, Hess P, Yang D D, Xu J, Turner T K, Nimnual A, Bar-Sagi D, Jones S N, Flavell R A and 
Davis R J (2000) Requirement of JNK for Stress-Induced Activation of the Cytochrome C-
Mediated Death Pathway. Science 288: pp 870-874. 
Tsujimoto Y, Finger L R, Yunis J, Nowell P C and Croce C M (1984) Cloning of the Chromosome 
Breakpoint of Neoplastic B Cells With the T(14;18) Chromosome Translocation. Science 226: pp 
1097-1099. 
Vander Heiden MG, Chandel N S, Williamson E K, Schumacker P T and Thompson C B (1997) Bcl-XL 
Regulates the Membrane Potential and Volume Homeostasis of Mitochondria [See Comments]. 
Cell 91: pp 627-637. 
Vera MD and Joullie M M (2002) Natural Products As Probes of Cell Biology: 20 Years of Didemnin 
Research. Med Res Rev 22: pp 102-145. 
Verhaegen S, McGowan A J, Brophy A R, Fernandes R S and Cotter T G (1995) Inhibition of Apoptosis 
by Antioxidants in the Human HL-60 Leukemia Cell Line. Biochem Pharmacol 50: pp 1021-1029. 
H.  Bibliography 98 
Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C (1995) A Novel Assay for Apoptosis. 
Flow Cytometric Detection of Phosphatidylserine Expression on Early Apoptotic Cells Using 
Fluorescein Labelled Annexin V. J Immunol Methods 184: pp 39-51. 
Villunger A, Egle A, Kos M, Hartmann B L, Geley S, Kofler R and Greil R (1997) Drug-Induced 
Apoptosis Is Associated With Enhanced Fas (Apo-1/CD95) Ligand Expression but Occurs 
Independently of Fas (Apo-1/CD95) Signaling in Human T-Acute Lymphatic Leukemia Cells. 
Cancer Res 57: pp 3331-3334. 
Wahl M, Jensen P R and Fenical W (1994) Chemical Control of Bacterial Epibiosis on Ascidians. Mar 
Ecol Prog Ser 110: pp 45-57. 
Walczak H, Bouchon A, Stahl H and Krammer P H (2000) Tumor Necrosis Factor-Related Apoptosis-
Inducing Ligand Retains Its Apoptosis-Inducing Capacity on Bcl-2- or Bcl-XL-Overexpressing 
Chemotherapy-Resistant Tumor Cells. Cancer Res 60: pp 3051-3057. 
Walker NI, Harmon B V, Gobe G C and Kerr J F (1988) Patterns of Cell Death. Methods Achiev Exp 
Pathol 13: pp 18-54. 
Wilson KP, Black J A, Thomson J A, Kim E E, Griffith J P, Navia M A, Murcko M A, Chambers S P, 
Aldape R A, Raybuck S A and . (1994) Structure and Mechanism of Interleukin-1 Beta Converting 
Enzyme. Nature 370: pp 270-275. 
Wolter KG, Hsu Y T, Smith C L, Nechushtan A, Xi X G and Youle R J (1997) Movement of Bax From 
the Cytosol to Mitochondria During Apoptosis. J Cell Biol 139: pp 1281-1292. 
Xia Z, Dickens M, Raingeaud J, Davis R J and Greenberg M E (1995) Opposing Effects of ERK and 
JNK-P38 MAP Kinases on Apoptosis. Science 270: pp 1326-1331. 
Xue D and Horvitz H R (1995) Inhibition of the Caenorhabditis Elegans Cell-Death Protease CED-3 by a 
CED-3 Cleavage Site in Baculovirus P35 Protein. Nature 377: pp 248-251. 
Yamamoto K, Ichijo H and Korsmeyer S J (1999) BCL-2 Is Phosphorylated and Inactivated by an 
ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G(2)/M. Mol Cell Biol 19: 
pp 8469-8478. 
Yang J, Liu X, Bhalla K, Kim C N, Ibrado A M, Cai J, Peng T I, Jones D P and Wang X (1997a) 
Prevention of Apoptosis by Bcl-2: Release of Cytochrome c From Mitochondria Blocked. Science 
275: pp 1129-1132. 
Yang X, Khosravi-Far R, Chang H Y and Baltimore D (1997b) Daxx, a Novel Fas-Binding Protein That 
Activates JNK and Apoptosis. Cell 89: pp 1067-1076. 
Young PR, McLaughlin M M, Kumar S, Kassis S, Doyle M L, McNulty D, Gallagher T F, Fisher S, 
McDonnell P C, Carr S A, Huddleston M J, Seibel G, Porter T G, Livi G P, Adams J L and Lee J 
C (1997) Pyridinyl Imidazole Inhibitors of P38 Mitogen-Activated Protein Kinase Bind in the ATP 
Site. J Biol Chem 272: pp 12116-12121. 
Yuan J, Shaham S, Ledoux S, Ellis H M and Horvitz H R (1993) The C. Elegans Cell Death Gene Ced-3 
Encodes a Protein Similar to Mammalian Interleukin-1 Beta-Converting Enzyme. Cell 75: pp 641-
652. 
H.  Bibliography 99 
Yuan J and Yankner B A (2000) Apoptosis in the Nervous System. Nature 407: pp 802-809. 
Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles L A, Zon L, Kyriakis J, Liu F F and Woodgett J R 
(1996) The Stress-Activated Protein Kinase Pathway Mediates Cell Death Following Injury 
Induced by Cis-Platinum, UV Irradiation or Heat. Curr Biol 6: pp 606-613. 
Zhivotovsky B, Samali A, Gahm A and Orrenius S (1999) Caspases: Their Intracellular Localization and 
Translocation During Apoptosis. Cell Death Differ 6: pp 644-651. 
Zhou Q and Salvesen G S (2000) Viral Caspase Inhibitors CrmA and P35. Methods Enzymol 322: pp 143-
154. 
Zou H, Henzel W J, Liu X, Lutschg A and Wang X (1997) Apaf-1, a Human Protein Homologous to C. 
Elegans CED-4, Participates in Cytochrome C-Dependent Activation of Caspase-3. Cell 90: pp 
405-413. 
 
I.  Appendix 100 
I. Appendix 
1 Publications 
 
1.1 Abstracts 
Kirschke SO, Dirsch VM, Estermeier M, Steffan B, Vollmar AM. The marine alkaloid 
ascididemin triggers apoptosis by a mechanism that does not involve caspase activation 
upstream of mitochondria. Free Radical Biology and Medicine 2001 Nov, 31 (Supp 
1):316. Poster presentation at the 8th Annual Meeting of the Oxygen Society, Durham, 
North Carolina, USA (2001). 
 
Kirschke SO, Dirsch VM, Estermeier M, Steffan B, Vollmar AM. Apoptotic signaling 
of ascididemin, a marine pyridoacridine alkaloid. Naunyn-Schmiedeberg’s Archieves of 
Pharmacology 2002 Mar, 365 (Supp 1):40. Poster presentation at the 42. Tagung der 
deutschen Gesellschaft für klinische Pharmakologie und Toxikologie, Mainz, Germany 
(2002). 
 
 
1.2 Original publications 
Dirsch VM, Kirschke SO, Estermeier M, Steffan B, Vollmar AM. Apoptosis signaling 
triggered by the marine alkaloid ascididemin is routed via caspase-2 and c-Jun NH2-
terminal kinases to mitochondria.  
Submitted 09/2002. 
 
Feling N, Kirschke SO, Steglich W. Isolation and structural characterisation of 
Flettichromen, a cytotoxic secondary metabolite of Albatrellus flettii.  
In preparation. 
 
 
I.  Appendix 101 
2 Acknowledgements 
I would like to sincerely thank Prof. Dr. Angelika M. Vollmar for giving me the 
opportunity to pursue the doctoral thesis in her research group. Her trust, 
encouragement and continuous availability for discussion were very helpful for 
successful work.  
Special thanks go to my thesis committee, especially to the coreferee Prof. Dr. Ernst 
Wagner. 
I am deeply grateful to Dr. Verena Dirsch for her continuous support of my work, 
inspiring discussions and very helpful professional advices at any time. 
I would like to thank Michael Estermeier for sufficient supply of ascididemin. 
Sincere thanks are given to all members of the research group for cooperativeness and a 
pleasant working atmosphere, especially to the following people: 
A lot of thanks go to Ursula Haider, Stefanie Kulhanek-Heinze, Melanie Keller and 
Constanze von Schenck for their friendship, unlimited helpfulness, encouragement and 
for the great time in- and outside the laboratory. 
Thanks are given to Thomas Räthel und Julia Traxel contributing to enjoyable 
laboratory working. 
Many thanks also to Hans-Peter Keiss and Dr. Tobias Gerwig for patiently assisting in 
all kinds of computer problems.  
I am indebted to Dr. Rainer Samtleben for his helpfulness. His professional knowledge 
and experience was auxiliary for both my work and for teaching students. 
I would like to thank Ursula Kollmansberger for helpful technical assistance during 
practical courses for students. 
I am grateful to Brigitte Weiss, Rita Socher and Katharina von Gersdorff for their 
motivated laboratory assistance. 
I also would like to thank Amélie Mainka for her secretarial work and Veronika Rickl 
for giving me a hand in graphic design of posters and presentations. 
I am much obliged to SFB 369, not only for financial support but also for very good 
scientific cooperation, especially Prof. Dr. Gerhard Wanner, Dr. Eva-Maria Natzer and 
Prof. Dr. Wolfgang Steglich.  
I.  Appendix 102 
3 Curriculum vitae 
 
Persönliche Daten 
Name:    Stephanie Olivia Kirschke 
Geburtstag und -ort:   25.07.1974, München 
Staatsbürgerschaft:  deutsch 
 
Studium 
02/2000-12/2002 Promotionsstudium Pharmazeutische Biologie am 
Lehrstuhl von Fr. Prof. Dr. A. M. Vollmar;       
Department Pharmazie – Zentrum für Pharmaforschung, 
Ludwig-Maximilians-Universität München 
14.12.1999   Approbation als Apothekerin  
02.12.1999   Drittes Staatsexamen Pharmazie 
05/-11/1999   Pharmaziepraktikum bei Hexal AG, Holzkirchen 
11/1998-05/1999  Pharmaziepraktikum in der UNNA-Apotheke, Hamburg 
11/1998   Zweites Staatsexamen Pharmazie 
09/1996   Erstes Staatsexamen Pharmazie 
10/1994-09/1998 Pharmaziestudium an der Ludwig-Maximilians-
Universität München 
08/1993-09/1994  Sprachstudium, Florenz und Paris 
 
Schulausbildung 
09.07.1993   Abitur 
1984-1993 Peter Dörfler-Gymnasium, Marktoberdorf  
1980-1984   St. Martin-Grundschule, Marktoberdorf 
